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The most exciting phrase to hear 
in science, the one that heralds 
new discoveries, is not 'Eureka' but 
'That's funny ...' 
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ABSTRACT 
Cytochrome P450s (CYPs) are responsible for approximately 75% of the phase I-
dependent drug metabolism. Several important polymorphisms in these enzymes are 
known to significantly affect the individual drug response. CYP2C9 and CYP2C19 
are   polymorphically expressed CYP family members which are responsible for the 
metabolism of many different clinically important drugs, e.g. anticoagulants, 
antidepressants and antiulcer drugs. This thesis focuses on novel aspects with regard 
to the regulation of CYP2C9 and CYP2C19 gene expression. 
The influence of the recently found common allele variant CYP2C19*17 on 
CYP2C19 enzyme activity towards two CYP2C19 substrates was investigated in the 
frame of two pharmacokinetic in vivo studies. The studies compared the single-dose 
pharmacokinetics of omeprazole and the steady-state kinetics of escitalopram in 
healthy CYP2C19*17/*17 carriers with the pharmacokinetic outcome obtained for 
CYP2C19 wild-type subjects. While no significant differences in the metabolic 
efficacy were observed for escitalopram, CYP2C19*17/*17 subjects showed 
significantly lower plasma levels of omeprazole compared to CYP2C19 wild type 
carriers. This observation suggests that CYP2C19*17/*17 carriers might be at a higher 
risk for therapy failure during treatment with proton pump inhibitors.  
The transcriptional regulation of CYP2C9 and CYP2C19 gene expression by GATA 
transcription factors and by estrogen receptor α (ERα) was investigated in vitro. In the 
proximal promoter regions of both the CYP2C9 and the CYP2C19 gene, two adjacent 
putative GATA-binding sites with an ER-binding half-site in their vicinity were 
predicted in silico and initially studied by luciferase gene reporter assay. HepG2 and 
Huh-7 hepatoma cells were transfected with CYP2C9 or CYP2C19 promoter fragment 
carrying pGL3basic-constructs along with expression vectors for the transcription 
factors GATA-2, GATA-4, or ERα. Luciferase activities driven by wild-type 
CYP2C19 or CYP2C9 promoter were highly increased by GATA-4 and GATA-2 in 
both cell lines, whereas mutations introduced into the GATA binding sites or the co-
transfection of the GATA-4 antagonist FOG-2 caused a significant loss of luciferase 
activity. In contrast, treatment with estradiol derivatives of ERα-transfected cells 
caused a significant inhibition of CYP2C19 and CYP2C9 promoter activity that was 
antagonized by site-directed mutagenesis of the putative ERα-binding half-sites. 
Additionally, estradiol derivatives significantly suppressed both CYP2C9 and 
CYP2C19 mRNA expression in human hepatocytes, as measured by real time PCR. 
Electrophoretic mobility shift assays revealed sequence-specific binding of GATA-4, 
GATA-6, and ERα to the two adjacent GATA binding sites and to the predicted ER 
binding half sites, respectively. ChIP assay in the cultured cells furthermore confirmed 
the association of both GATA-4 and ERα with CYP2C9 and CYP2C19 gene 
promoter. In conclusion, we have established novel mechanisms of CYP2C9 and 
CYP2C19 transcriptional regulation that involve transcription factors from the GATA 
family and estrogen receptor α. The estrogen mediated regulation may explain the 
clinically observed inhibitory effects of oral contraceptives on CYP2C19 and 
CYP2C9 activity. 
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1 INTRODUCTION 
 
1.1 CYTOCHROME P450 ENZYMES AND PHARMACOGENETICS  
Cytochrome P450 enzymes (CYPs) belong to a large protein family and are 
the most important group of xenobiotic metabolizing enzymes in humans. 
CYPs are particularly abundantly expressed in the liver, where they play a 
critical role in determining the bioavailability of a wide range of important 
drugs. It is estimated that CYPs are responsible for approximately 75% of 
phase I-dependent drug metabolism. Furthermore, CYPs are involved in the 
transformation of a large amount of dietary constituents and endogenous 
chemicals (Ingelman-Sundberg, 2004a). While members of the families 
CYP4 to CYP51 are involved in metabolism of endogenous substrates such as 
steroids, fatty acids and prostaglandins, the isoenzymes of the families CYP1, 
CYP2 and CYP3 are collectively responsible for the biotransformation of the 
majority of therapeutics used in clinics (Ingelman-Sundberg et al., 2007). The 
human genome comprises 57 CYP genes and approximately the same number 
of pseudogenes, which are grouped into 18 families and 44 subfamilies 
according to their sequence similarity (Nebert, 1999).  
CYPs are characterized by a wide interindividual and intraindividual 
variability in enzyme activity. Major sources of these differences in enzyme 
activity are environmental factors, e.g. enzyme inhibition or induction by 
xenobiotic substances including drugs, biological factors including gender, 
hormonal state or disease state, and genetic variability. For many CYP genes 
genetic variants have been described caused by single nucleotide 
polymorphisms (SNPs), insertions/deletions or gene copy number variation 
(CNVs). The consequences are abolished, decreased, normal or increased rate 
of drug metabolism. The consequent variation in drug plasma levels can 
either result in adverse effects or lead to reduced therapeutic efficacy.  
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The field of 'pharmacogenetics' studies the variability in drug response due to 
heredity. Genetic variability in drug metabolism as reflected in differences in 
clearance, half-life, or maximal plasma concentration of a drug can be 
considered for individual genotype-based dose adjustments. Systematic use of  
pharmacogenetic information should help to improve the number of therapy 
responders, decrease the number of patients suffering from adverse drug 
reactions, thus reducing the risk of drug induced morbidity and mortality 
(Nebert, 1999; Ingelman-Sundberg et al., 2007; Seeringer and Kirchheiner, 
2008).  
 
1.2 CYP2C19 - GENE AND PROTEIN 
 
1.2.1  Polymorphisms in the CYP2C19 gene 
CYP2C19 is mainly expressed in the liver, but has also been detected in the 
duodenum (Klose et al., 1999; Lapple et al., 2003). The enzyme is involved in 
the metabolism of approximately 5% of drugs currently used in clinics 
(Ingelman-Sundberg, 2004b). Important CYP2C19 substrates include proton 
pump inhibitors (e.g. omeprazole, lansoprazole, pantoprazole), diazepam, the 
selective serotonin reuptake inhibitors (SSRI) citalopram and escitalopram, 
the anti-malaria drug proguanil, and the anti-coagulant clopidogrel (Herrlin et 
al., 2000; Klotz et al., 2004; Schwab et al., 2004; Ingelman-Sundberg et al., 
2007; Mega et al., 2009).  
The CYP2C19 gene, which is localized on chromosome 10, is highly 
polymorphic. More than 20 different alleles have been described for 
CYP2C19, located in both the 5´-flanking region as well as in coding and 
noncoding parts of the gene (Sim and Ingelman-Sundberg, 2006). However, 
only a few of these variants have been characterized with regards to their 
potential to modulate the metabolic capacity of CYP2C19. Individuals can be 
classified according to their CYP2C19 genotype and the associated CYP2C19 
enzyme activity. Thus, subjects can be divided into extensive metabolizers 
(EM; homozygous or heterozygous for the wild type allele), intermediate 
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metabolizers (IM; one mutant allele responsible for the slow metabolizer 
phenotype), poor metabolizers (PM; two mutant alleles responsible for the 
slow metabolizer phenotype), or ultrarapid metabolizers (UM; carriers of the 
promoter SNP CYP2C19*17) (Sim et al., 2006). Compared to EMs, PMs are 
to a lesser extent able to metabolize CYP2C19 substrates, as shown in several 
in vivo studies using classical CYP2C19 probe drugs such as S-mephenytoin 
or omeprazole (de Morais et al., 1994; Chang et al., 1995; Masimirembwa et 
al., 1995; Jurima-Romet et al., 1996; Roh et al., 1996; Furuta et al., 2005).  
Several alleles have been described, which are responsible for the occurrence 
of a PM phenotype, when present in a homozygous manner. The most 
common defective variants in Caucasians and Asians are the alleles 
CYP2C19*2, which causes a splice defect, and CYP2C19*3, which leads to 
the formation of a premature stop codon (Klotz et al., 2004). Subjects 
homozygous for CYP2C19*2 or CYP2C19*3 do not express any CYP2C19 
protein. The interethnic variability in the distribution of the PM genotype is 
fairly high, ranging from approximately 2.8% in Caucasians to 23% in Asians 
(Xie et al., 1999; Desta et al., 2002). It has been shown that CYP2C19 PMs 
exhibit three to thirteen times higher exposure to proton pump inhibitors 
(PPIs) than EMs. In IMs the bioavailability of PPIs is two to four times higher 
than in EMs (Klotz et al., 2004). This has important clinical consequences: It 
was shown in several studies that PMs have significantly higher benefits from 
therapy with PPIs compared to EMs, as mirrored in e.g. higher Helicobacter 
pylori eradication rates during triple therapy with anti-ulcer drugs (Yang and 
Lin, 2010). On the other hand, PMs suffer more often from side effects 
induced by other CYP2C19 substrates such as diazepam or clopidogrel than 
EMs (Bertilsson, 1995; Mega et al., 2009).    
In 2004 two novel SNPs in the CYP2C19 gene were identified in our 
laboratory (Sim et al., 2006). These variants are in complete linkage 
disequilibrium and are localized in the 5’-flanking region of CYP2C19 at 
position -806 and at position -3402, together constituting the CYP2C19*17 
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allele. The allelic frequency of CYP2C19*17 was found to be 18% in both a 
Swedish and an Ethiopian population compared to only 4% in Chinese and 
1.3% in Japanese individuals (Sim et al., 2006; Sugimoto et al., 2008).  
A retrospectively performed genotyping study of a Caucasian cohort 
previously phenotyped for omeprazole metabolism revealed a significantly 
reduced omeprazole AUC of 40% in homozygous CYP2C19*17 carriers 
compared to CYP2C19 wild type carriers, as predicted from the metabolic 
ratios for omeprazole. Furthermore, in vivo hepatic transfections in male CD1 
mice (Charles River Laboratories, Uppsala, Sweden)  revealed that luciferase 
plasmids containing the CYP2C19*17 allele showed enhanced hepatic 
transcriptional activity compared to the corresponding wild-type promoter 
(Sim et al., 2006).  
Interestingly, the C>T exchange at position -806 creates a potential consensus 
DNA-binding motif for the members of the transcription factor family 
GATA. EMSA analysis revealed that -806T is indeed capable of forming 
complexes with proteins present in nuclear extracts of human liver. These 
observations led to the hypothesis that the T variant at position -806 
influences the transcriptional rate of the CYP219 gene (Sim et al., 2006). 
 
1.2.2 Important CYP2C19 substrates  
1.2.2.1  Omeprazole 
Omeprazole belongs to the group of proton pump inhibitors (PPIs). PPIs are 
first choice drugs for the treatment of peptic ulcers (PU) and their 
complications (e.g. bleeding), gastroesophageal reflux disease (GERD), 
nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal  
lesions, Zollinger-Ellison syndrome, dyspepsia, and eradication of 
Helicobacter pylori together with antibiotics (Shi and Klotz, 2008). As 
typical for PPIs, omeprazole binds selectively and irreversibly to the H+-K+-
ATPase in the parietal cells of the stomach and inhibits gastric acid secretion. 
Omeprazole is administered as racemic mixture and is transformed via two 
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major metabolic pathways, hydroxylation catalyzed by CYP2C19 and 
sulphoxidation catalysed by CYP3A4. The metabolism of omeprazole is 
enantioselective, whereby the R-enantiomer is mainly metabolized by 
CYP2C19 while the S-enantiomer is mainly transformed by CYP3A4 (Laine 
et al., 2003; Schwab et al., 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1:  The metabolic pathways of omeprazole  
 
An effective drug treatment with PPIs, such as omeprazole, is highly 
dependent on the CYP2C19 genotype (Ingelman-Sundberg, 2004b). 
CYP2C19 PMs show prolonged half-lives as well as significantly higher 
omeprazole AUCs compared to EMs (Chang et al., 1995; Sagar et al., 1998). 
In a study using 20 mg of omeprazole for the treatment of Helicobacter pylori 
infections in peptic ulcers, the observed cure rates were very low in EMs 
(25%), 50% in IMs, and complete (100%) in PMs (Furuta et al., 1998). 
 
1.2.2.2 Escitalopram 
Citalopram acts as a selective serotonin reuptake inhibitor (SSRI) in the 
central nervous system, and enhances serotonin-dependent  neurotransmission 
by enlarging the serotonin amount in the intersynaptic cleft (Milne and Goa, 
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1991). Citalopram is marketed as racemate; its S-enantiomer is sold as the 
self-contained drug escitalopram and appears to mediate the major 
antidepressant effect due to especially high affinity to the serotonin 
transporter (SERT) (Herrlin et al., 2003).  
 
 
 
 
 
 
 
 
 
 
 
Fig. 2: The metabolic pathways of citalopram 
 
Escitalopram is a well established drug in clinics and is used for the treatment 
of dysthymias and depression, as well as of anxiety disorders, obsessive 
compulsive disorder, substance abuse, and dementia-related behavioural 
disturbances. Escitalopram is mainly eliminated through the liver by N-
desmethylation to desmethylcitalopram (DCT) and didesmethylcitalopram 
(DDCT). CYP2C19 is mainly responsible for the first elimination step (Yu et 
al., 2003). The transformation of DCT to DDCT is catalyzed by CYP2D6. 
Both metabolites are considered to be inactive (Herrlin et al., 2003). A major 
problem in clinical use of escitalopram is given by the high interindividual 
variations in plasma levels, which can lead to a less effective clinical response 
or to a higher risk for the development of toxic drug effects. The observed 
differences in escitalopram plasma concentrations are considered to be at least 
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partly associated with interindividual differences in the activity of the 
polymorphic expressed  CYP2C19 (Yu et al., 2003; Rudberg et al., 2008). 
 
 
1.2.3 Transcriptional regulation of the CYP2C19 gene 
In phenotyping studies a wide range in individual CYP2C19 activities have 
been observed, which are only partly explained by polymorphic expression or 
by xenobiotic-induced modulation of CYP2C19 activity. Interestingly, 
CYP2C19 activity also varies significantly among homozygous extensive 
metabolizers (*1/*1carriers) (Chang et al., 1995; Sim et al., 2006). The 
reasons underlying such variability are still unknown.  
Considerable attention has recently been paid to the potential significance of 
transcriptional regulation of CYP2C19. In 2004 Arafeyene et al. predicted in 
silico a number of potential binding sites for transcription factors in the 
CYP2C19 5’-flanking region, including the progesterone receptor (PR), Hox 
proteins, GATA proteins, TATA box-binding protein (TBP), and Pbx-1 
(Arefayene et al., 2003). Later, Kawashima et al. identified and 
experimentally addressed the functional relevance of two neighbouring direct 
repeat-1 (DR1) elements within the first 200 bp of both the CYP2C9 and 
CYP2C19 promoters (Kawashima et al., 2006). Whereas all these sites were 
capable of binding the transcription factor hepatocyte nuclear factor-4α 
(HNF-4α), transactivation by HNF-4α was only shown for the CYP2C9 
promoter. However, silencing experiments in human hepatocytes knocking 
down HNF-4α recently showed that HNF-4α is important for rifampicin-
mediated upregulation of CYP2C19 gene expression (Rana et al., 2010). 
Furthermore the mRNA expression levels of CYP2C19 were recently found 
to be significantly associated with the HNF-4α content in twenty human 
liver samples, underlining the important role of HNF-4α in maintaining the 
basal CYP2C19 expression (Wortham et al., 2007). Chen et al. identified a 
putative CAR/PXR-responsive element and a putative glucocorticoid receptor 
(GR) responsive element further upstream within the first 2 kb of the 5´-
 
Introduction 
 
 8 
flanking-region of the CYP2C19 gene, which were transactivated by 
CAR/PXR, and GR in HepG2 cells and enhanced the CYP2C19 promoter 
activity upon treatment with rifampicin and dexamethasone, respectively 
(Chen et al., 2003). Bort et al. described three putative HNF-3 binding sites 
within the first 610 bp of the CYP2C19 5`-flanking region and showed that 
CYP2C19 mRNA expression is significantly upregulated by HNF-3γ in 
HepG2 cells (Bort et al., 2004).  
 
 
Fig. 3: Functionally confirmed and putative transcription factor binding sites within CYP2C9 
and CYP2C19 promoters. The checked boxes show HNF-4α binding sites, which appear not 
to be functional 
 
 
It still remains to be elucidated how these transcription factors contribute 
alone or in concert to the observed interindividual differences in CYP2C19 
expression and activity. 
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1.3    CYP2C9 - GENE AND PROTEIN 
 
1.3.1 General aspects of CYP2C9 
CYP2C9 shows a wide range in interindividual hepatic expression levels and 
is the second most abundantly expressed CYP enzyme in the human liver 
(Miners and Birkett, 1998). CYP2C9 is also expressed in several extrahepatic 
tissues including kidneys, gut, brain, heart, aorta and other vessels, as well as 
in lungs (Klose et al., 1999; Delozier et al., 2007). It has been estimated that 
CYP2C9 metabolizes approximately 16% of all clinically prescribed drugs 
(Chen et al., 2004). This includes many important therapeutics like phenytoin, 
tolbutamide, warfarin, torasemide, losartan and several NSAIDs. Some of 
these drugs are characterized by a small therapeutic window (Urquhart et al., 
2007). Furthermore, CYP2C9 is, similarly to CYP3A4 and CYP2B6, 
inducible by exposure to the agents dexamethasone, rifampicin, 
phenobarbital, and hyperforin (Gerbal-Chaloin et al., 2001).  
The involvement of CYP2C9 in warfarin metabolism has particularly 
important clinical consequences. Warfarin has a narrow therapeutic window: 
Too low dosing increases the risk of thrombosis, whereas doses too high are 
associated with a higher incidence of serious bleeding (Urquhart et al., 2007). 
The inducibility of CYP2C9 and its polymorphic expression explain some of 
the variation in interindividual responses to warfarin (Peyvandi et al., 2004).  
CYP2C9 has also important physiological functions. The enzyme is involved 
in the endogenous generation of vasoactive molecules such as 
epoxyeicosatrienoic acids (EETs) and hydroxyeicosatrienoic acids (HEETs) 
from arachidonic acid in both liver and extrahepatic tissues. EETs play a 
critical role in vascular homeostasis as endothelial-derived hyperpolarizing 
factors (EDHF) and are as signalling molecules involved in the promotion 
of endothelial cell proliferation, migration and angiogenesis (Fleming, 2001; 
Fleming, 2008).  
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1.3.2 Polymorphisms in CYP2C9  
More than 50 SNPs have been described in both the exonic and intronic 
regions of the CYP2C9 gene (Sim and Ingelman-Sundberg, 2006). 
Furthermore, more than 520 variants have been detected in the 5’ upstream 
region of the gene (Zhou et al., 2009). However, only two common coding 
variants, termed CYP2C9*2 (the missense mutation 430T>C causing the 
amino acid substitution R144C (Rettie et al., 1994) and CYP2C9*3 (the 
missense mutation 1075A>C on exon 7 leading to the I359L substitution) 
(Sullivan-Klose et al., 1996), have functional consequences for enzyme 
activity, having allele frequencies of around 11% (CYP2C19*2) and 7% 
(CYP2C19*3) in white subjects. They occur at much lower frequencies in 
African and Asian populations (Kirchheiner et al., 2004). Both genetic 
variants lead to reduced enzyme activity and thereby to a less effective 
metabolism towards CYP2C9 substrates, such as warfarin or S-naproxen. 
CYP2C9*2 and CYP2C9*3 have been associated with a higher risk for drug 
side effects in patients treated with coumarin derivatives, such as warfarin 
(Kamali and Wynne, 2010). Both polymorphisms lead to significantly lower 
hydroxylation rate of S-warfarin and have a strong impact on the intrinsic 
clearance of this drug. Therefore carriers homozygous for CYP2C9*2 or 
CYP2C9*3 require smaller loading and maintenance doses of warfarin and 
have a four-fold increase in risk of bleeding complications, particularly at 
the beginning of a warfarin therapy (Gage and Lesko, 2008) 
 
1.3.3    Transcriptional regulation of the CYP2C9 gene in the 
liver and in liver-derived cell lines 
As for CYP2C19, the transcriptional regulation of the CYP2C9 gene is not 
completely understood yet. PXR, CAR, and GR have been implicated in 
regulating CYP2C9 expression. Chen et al. showed that PXR binds to two 
PXR/CAR-responsive elements within the first 3 kb of the CYP2C9 5’-
flanking region and mediates the induction of CYP2C9 by rifampicin, 
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hyperforin, and phenobarbital (Chen et al., 2004). The more proximally 
localized PXR/CAR-binding element at position -1839/-1824 is also able to 
bind vitamin D receptor (VDR) in vitro and to mediate a modest upregulation 
of CYP2C9 promoter by 1,25-hydroxyvitamin D3 (Drocourt et al., 2002). 
Moreover, induction of CYP2C9 mRNA expression by dexamethasone and 
phenobarbital is likely to be mediated by several GR and CAR response 
elements within the CYP2C9 promoter (Gerbal-Chaloin et al., 2001; Ferguson 
et al., 2002; Chen et al., 2004). HNF-4α and HNF-3γ are important regulators 
of the constitutive expression of CYP2C enzymes. Both transcription factors 
have been shown to modulate the basal expression of CYP2C9 (Jover et al., 
2001; Ferguson et al., 2002; Bort et al., 2004; Chen et al., 2005). Kawashima 
et al. could show that an HNF-4α mediated modulation of CYP2C9 promoter 
activity is mediated by two proximally located DR1 binding elements at 
positions -150/-138 and -185/-173 (Kawashima et al., 2006). Several possible 
binding sites for HNF-3γ have been detected within the 5’-flanking region of 
CYP2C genes. HNF-3γ-dependent activation of CYP2C9 has been proven 
both on the mRNA level and in reporter gene studies (Bort et al., 2004). 
Furthermore, CYP2C9 expression seems to be modulated by the transcription 
factor C/EBPα. The C/EBPα effect is mediated by a CCAAT box element 
within the proximal promoter of CYP2C9 (Ibeanu and Goldstein, 1995). 
In addition to the described isolated effects of various transcription factors on 
CYP2C9 promoter activity, regulatory proteins mediate their influence on the 
expression of CYP2C9 by interacting with each other or by interaction with 
further co-factors. For example, HNF-4α synergistically enhances the 
promoter activity of CYP2C9 with CAR and PXR (Chen et al., 2005). HNF-
4α moreover interacts with the co-activators SRC-1 and PGC-1α, whereby 
promoter enhancement of CYP2C9 by especially PGC-1α is highly dependent 
on HNF-4α abundance (Martinez-Jimenez et al., 2006). 
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1.4   ESTROGENS  
 
1.4.1  Endogenous synthesis 
Steroid hormones are synthesized from cholesterol via production of 
pregnenolone. Especially two organs in humans are capable of converting 
cholesterol into different active hormones. The adrenal cortex is able to 
produce cortisol (glucocorticoid), aldosterone (mineralocorticoid) and 
androgens, the gonads synthesize either estrogen and progesterone (ovary) or 
testosterone (testis). The production of steroid hormones is controlled by the 
hypothalamic-pituitary axis.  
 
 
 
 
 
 
 
 
 
 
 
 
Estrogens are especially synthesized in the theca and granulosa cells of the 
preovulatory graafian follicle and in the postovulatory corpus luteum in the 
ovary. Minor estrogen amounts are produced in testis, in the adrenal cortex as 
well as in the fat tissue. In the first metabolic step pregnenolone is formed 
from cholesterol, which is further hydroxylated and desmethylated to the 
weak androgens dehydroepiandrostenone (DHEA) and androstendione. After 
aromatization the most important estrogens estrone and estradiol are formed. 
The liver is finally able to convert estradiol to the weak estrogen estriol. The 
Enzymes: 
1     20,22-desmolase 
2     steroid-17α-hydroxylase 
3     17,20-desmolase    
4     17β-hydroysteroid-dehydrogenase 
5,6  Type II 3β-Hydroxysteroid  
       Dehydrogenase, Δ4,5 -Isomerase 
7     CYP19 (Aromatase activity) 
8     5α-Reductase 
9    P450 dependent hydroxylation in the liver 
 
 
 Fig. 4: Biosynthesis of sex steroids. 
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two major progestins progesterone and 17α-hydroxyprogesterone are formed 
in a metabolic side way by transformation of pregnenolone. 
 
1.4.2 The hypothalamic-pituitary-ovarian axis  
The hypothalamic-pituitary axis is responsible for the regulation of the 
estrogen/progesterone production of the ovary and, thus, responsible for the 
hormone/menstrual cycle of the woman. Neurons of the hypothalamus 
synthesize and release gonadotropin-releasing hormone (GnRH) in a pulsatile 
manner. The hormone binds to receptors at the anterior pituitary and 
stimulates the release of the gonadotropins follicle-stimulating hormone 
(FSH) and luteinizing hormone (LH). During the first half of the menstrual 
cycle elevated FSH levels lead to the maturation of the follicle in the ovary 
and stimulate aromatase production needed for estradiol synthesis in the 
granulosa cells of the follicle.  
 
 
 
Fig.5 A) The hormonal cycle of a woman. Steep raises of LH and FSH are reached during the 
preovulatory phase, leading to the rupture of the follicle. B) Estrogens are inhibiting the 
anterior pituitary during early follicle phase. Two days before ovulation high estrogen levels 
have a positive effect on LH and FSH production. Progestins lower the frequency of LH 
pulses and higher the amplitude of them. Figures adapted from (Boron, 2009) and (Aktories 
and Forth, 2009)  
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The aromatase converts androstendione to estrone, which is itself further 
converted to estradiol. LH is meanwhile stimulating the androstendione 
synthesis in the theca cells of the maturating follicle.  
The androgens are diffusing into the granulosa cells and are here finally 
aromatized to estrogens. The peak level of FSH is reached one day before a 
steep raise of LH which characterises the ovulation with is characterized by 
the rupture of the graafian follicle. The high LH levels stimulate especially a 
high production of progesterone by the theca-lutein cells of the corpus luteum 
during the luteal phase. High levels of progesterone inhibit follicular growth 
during this phase. Luteal function begins to decrease around 11 days after 
ovulation and ends with the demission of the corpus luteum.  
 
1.4.3  The Estrogen Receptor  
1.4.3.1  The family of nuclear receptors (NRs) 
The estrogen receptor family belongs to the large protein group of 
nuclear/steroid receptors, most of which are ligand-dependent transcription 
factors. There are around 50 different nuclear receptors known at the moment 
(selected members shown in Table 1). NRs have several characteristics in 
common. They are structurally composed of six functional regions (A–F) 
showing various degrees of sequence conservation. The N-terminal A/B 
domain is not well conserved among NRs, and harbours the transactivation 
domain AF-1.  The highly conserved C region comprises the DNA-binding 
domain (DBD) and the conserved E region contains the ligand-binding 
domain (LBD). The two remaining regions, D, a linker peptide between the 
DBD and the LBD and F, the C-terminal extension region of the LBD are 
again of variable size and are not conserved. The LBD binds agonistic or 
antagonistic ligands (e.g. hormones, vitamins, or toxins). The DBD is 
composed of two zinc fingers. The typical domain composition of NRs is 
shown on figure 6. 
An often occurring scenario is that NRs homo- or heterodimerize after ligand 
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binding. The NR dimer travels from the cytoplasm into the nucleus, binds to 
its specific consensus sequence in the target gene promoters and modulates 
gene expression. The recognition sites for NRs comprise typically a pair of 5 
to 6 bp long DNA sequences (two half sites) which are often separated by a 
spacer of 1 to 6 bases of length. 
 
      Table 1.  Selected members of the NR family 
 
 
 
1.4.3.2 The estrogen receptors – physiology of action 
Estrogen receptors (ERs) mediate estrogenic effects. There are two types of 
ERs: ERα and ERβ. Particularly ERα is responsible for physiological 
reproductive functions and reproductive behaviour (McDevitt et al., 2008). 
ERα is ubiquitously expressed and is especially abundant in endometrial 
tissue, mammary glands, bone tissue, blood vessels, and hypothalamus, in 
which it mediates estrogen-dependent tissue development, and influences the 
bone density, the cardiovascular system, and the mating behaviour, and takes 
Receptor  Ligand  Subtypes  gene symbol 
TR  thyroid hormones  α, β  NR1A1, NR1A2 
ER  estrogens  α, β  NR3A1, NR3A2 
PR  progesterone    NR3C3 
AR  testosterone, DHT    NR3C4 
MR  mineralocorticoids  α, β  NR3C2 
GR  glucocorticoids    NR3C1 
VDR  vitamine D    NR1I1 
RAR  All‐trans retinoic acid  α, β, γ  NR1B1, NR1B2, NR1B3 
RXR  9‐cis‐retinoic acid  α, β, γ  NR2B1, NR2B2, NR2B3 
LXR  oxysterols  α, β  NR1H1, NR1H2, NR1H3 
FXR  bile acids    NR1H4 
PPAR  fatty acids, prostaglandins  α, γ, δ  NR1C1, NR1C2, NR1C3 
PXR  xenobiotics    NR1I2 
CAR  xenobiotics, androstane    NR1I3 
HNF‐4  fatty acids  α, γ  NR2A1, NR2A2 
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part in the regulation of the hypothalamic-pituitary axis. ERβ can be detected 
in the ovary, prostate, testis, lung, thymus, spleen, heart, and brain. (Hall and 
McDonnell, 2005). It has become evident that ERβ has functions that are 
distinct from ERα. Studies with knock-out mice have shown that that ERα is 
the main player in mediating female reproductive functions, whereas ERβ is 
more important in non-classical target tissues. Mice lacking ERβ develop 
hypertension, malignancies in colon and prostate, and show increased anxiety 
(Swedenborg et al., 2009). 
Both ERα and ERβ share modest overall sequence identity. The conservation 
is, however, significantly higher within the DBD and LBD domains (Fig. 6) 
(Hall and McDonnell, 2005).  
 
 
 
 
 
 
 
 
Fig. 6: Domain composition and amino acid similarity of ERα and ERβ. Numbers within the 
boxes represent the number of amino acid residues. The percentages denote the grade of 
amino acid homology. DBD, DNA-binding domain; LBD, ligand-binding domain. Adapted 
from  (Hall and McDonnell, 2005)  
 
Both ERα and ERβ show a similar affinity to 17β-estradiol, but have got 
different relative affinities towards several other synthetic or naturally 
occurring ligands (Barkhem et al., 1998).  
In the non-activated state, ERs are located in the cytoplasm and are bound to 
heat shock proteins (e.g. Hsp90), which block the DNA binding domain.  
Upon hormone binding the receptor dissociates from its chaperone molecules 
and undergoes a conformational change, which leads to dimerization and 
179 89 38 251 43
142 84 28 248 28
Domain                 A/B                C           D         E                      F
DBD             LBD
Homology 18% 97%        24%                  58%                 12%    
ERa
ERß
NH2
NH2
AF-1 AF-2
AF-2
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translocation of the receptor into the nucleus. ERα and ERβ can either homo- 
or heterodimerize, which can lead to the formation of ERα-ERα, ERα-ERβ or 
ERβ-ERβ complexes.  
Both ERα and ERβ preferentially bind to similar palindromic DNA consensus 
sequences (EREs) within their target promoters, which are composed of two 
GGTCA half sites (GGTCANNNTGACC). ERα is also able to bind to 
imperfect EREs or ERE half sites (van de Stolpe et al., 2004; Welboren et al., 
2009). ER binding to DNA leads to a relocation of central α-helices and the 
formation of a hydrophobic pocket which can bind co-activator or co-
repressor proteins.  
A large number of co-regulators can interact with ERs via binding the 
transactivation domains within the NH2-terminus (AF-1) and next to the LBD 
(AF-2). In some cells binding to both AFs is required for maximal 
transcriptional activity (McDonnell and Norris, 2002). Especially the AF-2 
domain has been studied concerning its co-regulator recruitment. Here, in 
particular co-activators of the p160 family are able to recruit histone 
acetyltransferases, such as p300 and CBP. Histone acetylation leads to the 
decondensation of the chromatin structure within the promoter regions of the 
target genes, which facilitates the binding of the general transcription 
initiation machinery (Kamei et al., 1996). Co-activators such as TRAP220 are 
able to directly interact with transcription-associated proteins, e.g. RNA-
polymerase II (Kang et al., 2002). In contrast, co-repressor proteins, such as 
RIP140, SMRT or NCoR, recruit proteins with histone deacetylase activity, 
which induce a more compact chromatin formation within the promoter 
region, thus impeding transcription. RIP140 can also occlude the access of 
coactivators to the AF-2 domain (Hall and McDonnell, 2005).  
 
Besides directly binding to their DNA consensus sequences (classical 
pathway), ERs can act via at least three non-classical pathways: ER activation 
can occur ligand-independently through second-messenger pathways that 
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alter the activity of intracellular kinases and phosphatases, resulting in an 
altered phosphorylation status of ER. Furthermore, ligand-activated ER can 
interact in an indirect manner with regulatory promoter regions through 
protein-protein binding. A typical example is the ER interaction with AP1-
consensus sequences through a binding to the transcription factors c-Fos and 
c-Jun. Finally, cell membrane-bound ER can influence cellular signalling 
pathways, which lead to activation of kinases that phosphorylate other 
transcription factors (McDevitt et al., 2008).  
 
1.4.4   Selective ER modulators (SERMs) 
SERMs are tissue-selective ER modulators, which differ from pure estrogen 
antagonists, such as ICI 182,780, in their ability to display tissue-selective ER 
agonist-antagonist activities. Typical examples for this substance group are 
the therapeutics tamoxifen and raloxifene. The estrogen-antagonistic effect of 
tamoxifen in the breast makes it a first-line therapy against ER-expressing 
breast cancer. However, tamoxifen shows in parallel estrogen-agonistic 
effects in the uterus and is therefore associated with a higher risk for the 
development of endometrial cancer. Raloxifene is used in therapy of 
osteoporosis, and does not have a stimulatory effect on the endometrial tissue. 
The mechanisms by which SERMs express both agonistic and antagonistic 
effects, are likely to be based on the fact that SERMs induce a spectrum of 
different AF-2 binding site conformations which define the recruitment of  
co-activators and/or co-repressors. Dependent on the AF-2 conformational 
change, on the exact promoter that is targeted, and on the abundance and 
expression level of co-activators and co-regulators in the cell,  tissue-selective 
ER-dependent modulation of gene expression is achieved.  
 
1.4.5  Oral contraceptives 
Ethinylestradiol (ETE), mestranol, and estradiol (EE) are estradiol derivatives 
mainly used in oral contraceptives (OCs) and hormone replacement therapy. 
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Whereas ethinylestradiol and mestranol are utilized in OC preparations, 
estradiol can be found in products used for hormone replacement therapy. In 
OCs the estradiol derivatives are commonly combined with progesterone 
derivatives to obtain better cycle control in women with intact uterus (Laine 
et al., 2003). 
The effect of OCs is based on the mechanism that contraceptive steroids exert 
negative feedback to the hypothalamic-pituitary axis, leading to suppressed 
secretion of the gonadotropins FSH and LH. Low FSH levels are responsible 
for insufficient folliculogenesis, whereas low LH levels inhibit ovulation. 
Progestins help to thicken the cervical mucus and thus inhibit sperm 
penetration into the uterus. Furthermore, they decrease uterus motility and 
induce changes in the endometrial tissue, making the endometrium more 
resistant against embryo implantation. 
 
1.4.6  Estradiol derivatives and their influence on CYP2C9 and 
CYP2C19 activity 
OC formulations are able to influence CYP2C19 dependent metabolism as 
shown in several in vivo studies with different CYP2C19 marker substances. 
OCs e.g. double the plasma AUC ratio of omeprazole/5-hydroxyomeprazole 
and the urinary metabolic (S)/(R) ratio of mephenytoin. Interestingly, the 
inhibitory effect on CYP2C19 activity was only observed during parallel 
treatment with combined oral contraceptives containing both ethinylestradiol 
and progestins, but not during a treatment with minipills, containing 
progestins only (Tamminga et al., 1999; Laine et al., 2000; Hagg et al., 2001; 
Palovaara et al., 2003).  
Furthermore, several studies have shown that estrogen-containing OC 
formulations are able to affect the pharmacokinetics and metabolism of  
several other drugs metabolized by CYP2C19 including propranolol, 
proguanil and selegenine (Walle et al., 1996; Laine et al., 1999; McGready et 
al., 2003). The observed OC related effects probably cannot be ascribed to an 
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inhibition of CYP2C19 alone as other CYP enzymes are also involved in the 
metabolism of the mentioned drugs. Both weak and strong inhibitory effects 
of estradiol derivatives on CYP2C19 activity have been also observed in 
vitro. Here the measured enzymatic activity of CYP2C19 towards 
mephenytoin and omeprazole was reduced in liver microsomes upon 
treatment with EE (Jurima et al., 1985; Laine et al., 2003; Rodrigues and Lu, 
2004).  A direct inhibitory effect on the CYP2C19 enzyme has been 
suggested as the mechanism behind the observed effects. 
 
The enzyme CYP2C9 has been found to be significantly inhibited by 
ethinylestradiol in vitro (Laine et al., 2003). Furthermore a genotype-
phenotype correlation study, which included individuals treated with the 
CYP2C9 substrate losartan revealed that high variation in losartan plasma 
levels observed within the CYP2C9 wild-type group was partly caused by the 
parallel intake of OCs during the study, as the use of OCs led to slower 
losartan metabolism (Sandberg et al., 2004). 
 
1.5  THE TRANSCRIPTION FACTOR FAMILY GATA AND ITS CO-
REGULATORS  
 
The GATA protein family comprises six members of evolutionarily 
conserved and widely expressed zinc finger transcription factors, GATA-1 to 
-6, which all recognize the DNA consensus motif (A/T)GATA(A/G).  
Especially the family founding member GATA-1 as well as GATA-2 and 
GATA-3 have been suggested to play a central role in the regulation of a 
number of important genes involved in the development and control of 
haematopoiesis and some ectodermal derivatives (Ohneda and Yamamoto, 
2002). GATA-4, -5 and -6 are especially abundantly expressed in cardiac 
tissue and endodermal derivatives (Peterkin et al., 2005) and have been 
shown to play a significant role in the transcriptional regulation of several 
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genes important for cardiac development and cardiomyocyte differentiation 
(Crispino et al., 2001; Peterkin et al., 2003; Brewer and Pizzey, 2006).  
 
 
Table 2: Expression profile of GATA proteins and their implication in the development of 
pathological phenotypes 
SUB‐
GROUP 
NAME  EXPRESSION PROFILE IN 
HUMANS 
* PHENOTYPIC EFFECTS WHEN  
MUTATED/ 
KNOCKED OUT** 
I  GATA‐1  Erythroid, eosinophil and  
mast cells, 
megakaryocytic lineages 
X anemia,
thrombocytopenia, 
dyserythropoietic anemia,  
early death of embryo 
GATA‐2  Early erythroid cells, 
mast cells, megakaryo‐
cytic lineages, multipo‐
tent progenitor cells, 
endothelial cells 
3 anemia,
thrombocytopenia, 
dyserythropoietic anemia, 
early death of embryo 
GATA‐3  T‐lymphocytes, 
developing parathyroid 
10 Hypoparathyreoidism, 
deafness, renal dysplasia 
II  GATA‐4  heart, gut, ovary, testis, 
liver, small intestine 
8 hypoplastic myocardium, 
cardia bifida, septal defects 
early death of embryo 
GATA‐5  Heart, small intestine 20
GATA‐6  pancreas, adrenal cortex, 
ovary,  testis, lung, liver, 
brain, small intestine 
18
*    Chromosome 
**  Mutations in humans or in animals; knock out in animal experiments 
 
GATA-4 is also abundantly expressed in the liver where it is involved in the 
regulation of expression of albumin (Bossard and Zaret, 1998), erythropoietin 
(Dame et al., 2004) and Hex homeodomain proteins (Denson et al., 2000).  
 
All GATA proteins have two highly conserved zinc fingers, which comprise 
the DNA-binding domain. It seems that especially the C-terminal zinc finger 
and its adjacent basic domain are required for DNA sequence recognition and 
DNA-binding. Studies on GATA-1 revealed that the N-terminal zinc finger 
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does not contact DNA directly during binding to a single consensus motif 
(Visvader et al., 1995; Morrisey et al., 1997). The N-terminal zinc finger 
rather seems to stabilize the DNA-binding and to assure binding specificity 
(Whyatt et al., 1993). However, in case of two adjacent GATA binding sites, 
which often occur in vertebrate genes, both zinc fingers are required for high 
affinity DNA-binding. Furthermore both zinc fingers can directly interact 
with other regulatory proteins (Trainor et al., 2000; Brewer and Pizzey, 2006).   
GATA genes have been shown to be strongly conserved in mammals. All 
GATA genes possess at least one non-coding exon and the zinc fingers are 
encoded on separate exons. Especially the cardiac subgroup GATA-4, 
GATA-5 and GATA-6 show very high homology in their DNA-binding 
domains but diverge considerably in their N- and C-terminal regions, which 
contain the transcription activation modules (Temsah and Nemer, 2005).  
Fig. 7: Domain composition and amino acid similarity of GATA-4, GATA-5 and GATA-6 in 
vertebrates. Numbers within the boxes represent the percentage of amino acid similarity 
towards GATA-4. DBD, DNA-binding domain; ZF, zinc finger; NLS nuclear localisation 
signal; TAD transactivation domain; blue circle: MAPK phosphorylation site; orange circle: 
PKA phosphorylation site, grey circle: PKC phosphorylation site. In brackets: longer GATA-
6 isoform. Figure adapted from  (Temsah and Nemer, 2005) and (Brewer and Pizzey, 2006) 
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GATA factors have been shown to interact with many co-regulatory proteins. 
Studies have been especially focussed on GATA-4-dependent promoter 
regulation of cardiac genes. Examples of interactive proteins that enhance a 
GATA-4-dependent promoter activation include Nkx2-5, MEF-2, SRF, 
dHAND, SMAD1/4, Tbx5, c-Fos, STAT proteins, YY1, Zfp260, and p300 
(Brewer and Pizzey, 2006).   
Besides co-activators, several co-repressors of GATA proteins have been 
described. Amongst them, a family of nuclear zinc finger proteins, which 
comprises the members FOG-1 and FOG-2 (Friend of GATA), plays an 
important role (Hirai et al., 2004). While FOG-1 has been shown to be co-
expressed together with GATA-1, -2, and -3 and to be involved in the 
differentiation of hematopoietic cell lineages (Tsang et al., 1997), FOG-2 is 
co-expressed with GATA-4, -5, and -6 in the heart throughout its 
development and in the adult (Lu et al., 1999; Svensson et al., 1999). In 
animal experiments it has been shown that FOG proteins are essential for the 
development of both the hematopoietic and cardiovascular system (Tsang et 
al., 1997; Lu et al., 1999; Svensson et al., 1999; Tevosian et al., 1999).  
Highest expression levels of FOG-2 are observed in the heart, brain, and 
testis. However, it has been also found, though at lower levels, in human liver 
(Lu et al., 1999; Svensson et al., 1999). FOG-2 interacts via its C-terminal 
zinc fingers 5 to 8 with the N-terminal zinc finger of GATA-4, -5 and -6, thus 
repressing GATA-mediated transcriptional activation of target promoters (Lu 
et al., 1999). Engineered mice in which the GATA-4/FOG-2 interaction is 
disrupted display cardiac malformations similar to those observed in FOG-2 
deficient embryos, suggesting that most of the functions by FOG-2 in the 
heart are mediated via its interaction with GATA-4 (Crispino et al., 2001). 
Recently, Roche et al. showed that the metastasis-associated proteins (MTA) -
1, -2 and -3, as well as the retinoblastoma proteins RbAp46 and RbAp48, 
interact with FOG-2 and are essential for the repressive effect of FOG-2 on 
GATA-4 activity (Roche et al., 2008).  
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In addition to its involvement in the expression of many genes important for 
cardiac and endocrine function (reviewed in (Brewer and Pizzey, 2006) and  
(Viger et al., 2008)), GATA-4 has also been shown to regulate the expression 
of drug-metabolizing enzymes and liver transporters, such as epoxide 
hydroxylase (Zhu et al., 2004) and the ATP-binding cassette transporters 
ABCG5 and ABCG8 (Sumi et al., 2007). Furthermore the expression of 
CYP19, one of the key genes in estrogen synthesis, is regulated by GATA-4 
(Cai et al., 2007). These data suggest that GATA-4 is also important for the 
expression of genes implicated in metabolism and transport of both 
endogenous and exogenous compounds. 
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2 AIMS 
 
The following in vitro and in vivo studies were performed to investigate how 
a polymorphic promoter site in CYP2C19 and specific transcription factors 
contribute to CYP2C9 and CYP2C19 expression and thereby to the observed 
interindividual variation in drug metabolism efficacy. 
Specifically, the following projects were included in my thesis: 
 
1. An in vivo study investigating the effect of CYP2C19*17 on 
omeprazole pharmacokinetics 
2. An in vivo study investigating the effect of CYP2C19*17 on 
escitalopram pharmacokinetics 
3. Investigation of transcription factor GATA-dependent regulation of 
CYP2C9 gene expression 
4. Investigation of transcription factor GATA-dependent regulation of 
CYP2C19 gene expression 
5. An in vitro study to investigate the influence of female sex steroids on 
CYP2C19 gene expression 
6. An in vitro study to investigate the influence of female sex steroids on 
CYP2C9 gene expression 
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3 COMMENTS ON METHODOLOGY 
 
3.1  BIOINFORMATICS 
 
Nucleotide sequences were obtained from the online database of the National 
Center for Biotechnology Information (NCBI, www.ncbi.nlm.nih.gov). 
Sequencing results for cloned promoter constructs were compared using the 
pairwise Basic Local Alignment (BLAST) algorithm of NCBI. Any identified 
mutations in promoter constructs, generated during PCR reactions, were 
corrected with the GeneTailor mutagenesis kit from Invitrogen (GeneTailor™ 
Site-directed mutagenesis, Invitrogen™). The corrected plasmids were 
resequenced and reblasted for control. Transcription factor binding sites were 
predicted using search engines, such as TESS 
(http://www.cbil.upenn.edu/cgi-bin/tess/tess) and Matinspector 
(http://www.genomatix.de/). 
 
3.2   CELL LINES AND CELL CULTURE 
 
In the in vitro studies described in this thesis the human hepatoma cell lines 
HepG2 and Huh7 as well as primary human hepatocytes were used. HepG2 
and Huh7 cells were used in transient cell transfection experiments as well as 
for the production of nuclear extracts used in EMSA experiments. These two 
cell lines were chosen as an in vitro model for the hepatic in vivo situation 
with the aim to mimic the hepatic transcription factor composition as well as 
possible. Furthermore, both cell lines are well transfectable with 
Lipofectamine™ 2000. A disadvantage of both cell lines is that CYP2C9 and 
CYP2C19 are very poorly expressed, so that e.g. measurements of RNA 
expression levels upon treatments with transcription factor ligands are not 
possible. Therefore, primary human hepatocytes were used to determine the 
changes in the endogenous expression level of CYP2C19 in Paper V. 
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For stable transfections of CYP2C19 cDNA, Flp-In™- 293 cells purchased 
from Invitrogen™ were used. This system allows integration of foreign 
cDNA into the cell genome at a specific Flp site at a transcriptionally active 
genomic locus within the cells. 
 
3.3  IN VITRO TRANSFECTIONS 
 
3.3.1  Transient transfections 
Transient transfections were performed using Lipofectamine™ 2000 
(Invitrogen™). With this method nucleic acids are introduced into cells with 
the help of cationic lipids. The lipids enclose the genetic material and deliver 
it to the inside of the cell by fusing with the outer cell membrane. As a result, 
the transfected nucleic acids are transiently expressed in one generation of a 
transfected cell line. 
Other transfection methods, which are not utilized in this thesis, differ mainly 
by the nature of the transfection reagent, which can also be based on e.g. 
calcium-phosphate, cationic polymers, or highly branched organic 
compounds.  
 
3.3.2  Establishment of a cell line stably expressing CYP2C19 
Stable transfections can be achieved by introducing the transfected DNA 
fragments into the cell genome, so that the foreign DNA can be passed to the 
next cell generations. In Paper V a stable cell line expressing CYP2C19 was 
constructed. For that purpose the Flp-In™ system comprising Flp-In™-293 
cells from Invitrogen™ were used. This specific cell line expresses the 
pFRT/lacZeocin fusion gene, which contains a single integrated Flp 
Recombination Target (FRT) site.  
In Paper V the cell line stably expressing CYP2C19 was established to 
measure enzyme activity in dependency of estradiol treatment. For that 
purpose CYP2C19 cDNA was inserted into the pcDNA5/FRT plasmid. This 
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construct was co-transfected into the Flp-In™- 293 cells together with the Flp 
recombinase expression plasmid pOG44 using Lipofectamine 2000. The 
expressed Flp recombinase mediates insertion of the expression construct, 
which carries the CYP2C19 cDNA into the cell genome at the FRT site 
through site-specific DNA recombination. Afterwards, single colonies 
resistant to Hygromycin B (Invitrogen™) were selected and subcultured. The 
selection of positive clones was performed by detection of CYP2C19 mRNA 
and measurement of enzyme activity as described in the next sections. Mock 
cells were transfected with pcDNA5/FRT empty plasmid and pOG44 and 
prepared as described above.  
 
3.4  GENE REPORTER ASSAYS 
 
Gene reporter assays are working with plasmid vectors that carry a reporter 
gene, which encode a well quantifiable protein. The reporter construct used in 
this thesis is the vector pGL3basic, which carries the reporter gene coding for 
the protein luciferase. The luciferase protein is able to catalyze the cleavage 
of a marker reagent which is added to the cell lysate. The metabolites emit 
fluorescent light. The amount of light is easily detected and measured and is 
proportional to the amount of expressed luciferase. The 5’-flanking promoter 
regions of genes are cloned in front of the luciferase gene, and regulate and 
modulate its expression. Thereby it is possible to measure the effect of a 
specific transcription factor on the subcloned gene promoter, e.g. by co-
transfecting and overexpressing the regulatory proteins of interest or by site-
directed mutagenesis of putative transcription factor binding sites within the 
subcloned promoter. 
In paper III and IV gene reporter assays were performed co-transfecting 
GATA-2–pCMV and GATA-4-pcDNA1.1 constructs together with 
pGl3basic plasmids carrying around 2 kb long 5’-flanking regions of CYP2C9 
or CYP2C19 into HepG2 and Huh7 cells. In paper V and VI the construct 
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ERα-pcDNA3.1 was co-transfected together with CYP2C19 promoter or 
CYP2C9 promoter carrying pGL3basic plasmid into Huh7-cells. Furthermore, 
site-directed mutagenesis (GeneTailor™ Site-directed mutagenesis, 
Invitrogen™) was utilized, to confirm any regulatory influence of putative 
GATA- and ER-binding sites within the CYP2C9 and CYP2C19 promoters.  
 
3.5  DETECTION OF CYP2C19 ENZYME ACTIVITY BY P450-
GLO™ ASSAY.  
 
In paper V the CYP2C19 enzyme activity dependent on ERα ligand treatment 
was quantified by measuring the catalytic activity towards a specific substrate 
in cells stably transfected with CYP2C19. For that purpose Flp-In™-
293/CYP2C19 cells were seeded into 96-well plates and incubated with 
increasing amounts of the CYP2C19 substrate Luciferin-H-EGE (Promega). 
Luciferin H-EGE is a luminogenic substrate which is converted to luciferin 
specifically by CYP2C19. The CYP2C19 activity was stopped by adding 
inhibitors and the amount of produced luciferin was detected by adding 
Ultra-Glo™ Luciferase enzyme (provided in the P450 Glo™ Assay, 
Promega) that generates a  luminescent signal. The produced luminescence, 
which is proportional to CYP2C19 activity, was measured in the cell medium 
using a TD-20/20 Luminometer (Turner Designs).  
 
3.6  ELECTROMOBILITY SHIFT ASSAY (EMSA) 
 
To investigate possible binding of the GATA transcription factors and ERα 
and ERβ to CYP2C9 and CYP2C19 promoter elements, EMSAs were carried 
out in papers III, IV, V and IV.  
The EMSA method uses oligonucleotides of 30-40bp in length, which 
comprise the in silico predicted transcription factor (TF) binding sites of 
interest. Reverse complementary oligonucleotides are hybridized to double 
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stranded fragments, which are radioactively labelled with 32P. Radiolabelled 
oligonucleotides are then incubated with nuclear proteins extracted from 
various cell lines or with in vitro translated proteins. Subsequently, the 
electrophoretic mobilities of the formed TF-oligonucleotide complexes are 
tested on a polyacrylamide gel. Supershift reactions using antibodies 
specifically interacting with the transcription factors of interest, reactions 
using binding site-specific mutated oligonucleotides and competition 
reactions with unlabelled oligonucleotides (cold probe) are executed to further 
specify the type of protein which binds to the DNA fragment and to confirm 
site-specific binding.  
In papers III to VI nuclear extracts from HepG2 and Huh7 cells were used in 
EMSA experiments. Furthermore, in vitro translated ERα protein was 
generated and utilized in EMSAs performed in paper V to further confirm 
ER-specific binding to the predicted ERE half-site. 
  
3.7  CHROMATIN IMMUNOPRECIPITATION ASSAY  
 
Chromatin immunoprecipitation (ChIP) assays investigate the protein-DNA 
interactions in living cells. In paper III to VI ChIP assays were carried out 
using HepG2 and Huh7 cells. In the ChIP assay, DNA-bound proteins are 
crosslinked with formaldehyde, DNA is sheared into fragments by sonication 
or by enzyme digestion, and protein-DNA complexes of interest are pulled 
down with the help of antibodies which specifically react with the 
transcription factor of interest. After reversing the crosslinks, the binding of 
the protein is finally confirmed by PCR reactions with specific primers for the 
DNA fragment, which the protein has been initially crosslinked to.  
In papers III and IV ChIP assays have been performed to investigate a 
possible interaction of GATA-4 with the proximal promoter of CYP2C9 and 
CYP2C19 and in paper V and VI to answer the question whether ERα binds 
to regulatory elements within CYP2C19 and CYP2C9 promoter.  
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3.8  QUANTITATIVE REAL TIME PCR 
 
To measure a putative increase or decrease in mRNA amount due to promoter 
induction or inhibition quantitative real time PCR methods using either SYBR 
Green (paper V) or the TaqMan® technology (paper VI) were employed. In 
paper V, a primer pair specific for the CYP2C19 mRNA was designed and 
used in the PCR reaction. In the first step reverse transcription was performed 
to obtain the cDNA template for the PCR reaction. Afterwards SYBR Green, 
a fluorescent marker, was added to the PCR reaction. SYBR Green 
intercalates between DNA strands. The amount of emitted fluorescence is 
therefore directly proportional to the amount of DNA produced in the PCR 
reaction. In paper VI CYP2C9 specific TaqMan® oligos were used. The 
Taqman® probes are characterized by a covalently bound fluorophore at the 
5’-end and a covalently bound quencher at the 3’-end of the primer. During 
PCR reactions the utilized polymerase unfolds a 5' to 3' exonuclease activity 
which destroys the probe that has annealed to the DNA template. As a 
consequence, the fluorophore is released and emits a fluorescent signal which 
is computational detected.  The signal is directly proportional to the amount 
of released fluorophore and therefore directly proportional to the amount of 
cDNA template (reverse transcribed mRNA) in the PCR reaction. CYP2C19 
and CYP2C9 mRNA measurements were normalized to the mRNA amount of 
the reference gene human TATA box binding protein (TBP). In paper V and 
VI, the technique of quantitative real time PCR was used to measure the 
amount of produced CYP2C19 or CYP2C9 mRNA in primary human 
hepatocytes in dependency of a cell treatment with different ERα ligands. 
 
3.9  IN VIVO PHENOTYPING OF CYP2C19*17 CARRIERS 
 
To evaluate the influence of the CYP2C19*17 allele on the enzymatic activity 
of CYP2C19 in vivo, two phenotyping studies with specific probe drugs for 
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CYP2C19 were designed and performed as described in papers I and II. In 
both studies 17 healthy volunteers, 12 genotyped as CYP2C19*1/*1 and five 
as CYP2C19*17/*17 carriers, were included. Genotype determination had 
been performed in advance with a nested PCR approach. Both studies were 
conducted as open-label, one phase trials. 
In paper I, 17 individuals were treated with a single dose of 40 mg 
omeprazole after a fasting period of at least 8 hours. After drug 
administration, 10 ml venous blood were drawn at time points 0.5, 1, 1.5, 2, 3, 
4, 6, 8, and 10 hours after treatment. Omeprazole and the two metabolites 5-
hydroxyomeprazole and omeprazole sulfone were quantified using a 
reversed-phase high-performance liquid chromatography (R-HPLC) method. 
Main kinetic parameters that were determined and compared in both genotype 
groups included the extrapolated AUC∞ (area under the curve), the total body 
clearance (CL), Tmax, Cmax and t1/2 for omeprazole and its metabolites. 
In paper II, the 17 participants earlier included in the omeprazole study were 
treated as outpatients with 5 mg of the probe drug escitalopram over 1 week. 
Participants were only allowed to take part after a wash out period of at least 
one week for omeprazole. At the last day of treatment steady state 
pharmacokinetics of escitalopram was determined by drawing blood samples 
at the time points 1.5, 3, 4, 5, 8, 10 and 12 h after the morning dose. 
Pharmacokinetic data were evaluated by determining the pharmacokinetic 
main parameter AUC1-12h for escitalopram and its main metabolite 
desmethylescitalopram. Homozygous CYP2C19*1 and CYP2C19*17 carriers 
were compared concerning their pharmacokinetic characteristics for 
escitalopram. In a last step a correlation analysis between escitalopram 
kinetics at steady state (AUC1-12h) and omeprazole single-dose kinetics 
(AUC∞) was performed to directly compare the in vivo behaviour of both 
drugs with respect to the CYP2C19 genotype. 
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3.10  STATISTICAL ANALYSIS 
 
Comparisons of pharmacokinetic data (AUC, CL, Tmax, Cmax, t1/2) in paper I 
and II were performed using the unpaired two-tailed t-test (paper I) or the 
Mann-Whitney-U test and the one-sided t-test (paper II). P-values < 0.05 
were considered as significant. The AUC1-12 and AUC∞ (Paper I and II) were 
calculated using the linear trapezoid rule. The extrapolation to infinity was 
performed with help of the log-linear terminal elimination phase (λz). The 
Spearman correlation coefficient was determined to correlate the AUC1-12 of 
escitalopram steady state kinetics determined in paper II with the AUC∞ of 
omeprazole single dose kinetics determined in paper I. 
In paper III and IV comparisons of luciferase activities obtained upon co-
transfections with GATA transcription factors mediating CYP2C19 and 
CYP2C9 promoter activity were performed using the one-way ANOVA 
followed by a Tukey’s post hoc test. P-values < 0.05 were considered as 
significant. 
In paper V and VI statistical comparisons of CYP2C19 and CYP2C9 promoter 
driven luciferase activities obtained upon co-transfections with ERα and ERα 
ligand treatment as well as real time PCR based mRNA level measurements 
after cell treatments with ERα ligands were performed using the one-sample 
t-test. Also here, p-values < 0.05 was considered to be significant. 
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4 RESULTS 
 
4.1 PAPER I – INFLUENCE OF CYP2C19*17/*17 ON 
OMEPRAZOLE   PHARMACOKINETICS IN VIVO 
 
To investigate, whether CYP2C19*17 has a significant impact on omeprazole 
metabolism in vivo, we performed a pilot study with 16 healthy individuals, 
which were either homozygous carriers of CYP2C19*17 (5 participants) or 
homozygous of CYP2C19*1 (11 individuals). The CYP2C19 genotype of all 
participants was determined by PCR/RFLP analysis before inclusion into the 
study. Sample size calculations for the study were based on the prior 
estimate of a 40% difference in omeprazole AUC between CYP2C19*1/*1 
and CYP2C19*17/*17 groups, which was considered to be significant (Sim 
et al., 2006). The subjects were treated with a single dose of 40 mg 
omeprazole and the main pharmacokinetic parameters of omeprazole 
obtained in both genotype subgroups were determined and compared.  
We found that the homozygous carriers of CYP2C19*17 exhibit significantly 
higher metabolic activity towards omeprazole, when compared to the wild-
type carriers (p=0.04). This observation is especially reflected in a twice as 
high AUC∞ of omeprazole and a twofold higher AUC∞ ratio of omeprazole/5-
hydroxy omeprazole in CYP2C19 wild-type carriers compared to the ratio 
calculated for CYP2C19*17 carriers. Furthermore, CYP2C19*17 carriers 
showed 3-fold lower levels of the metabolite omeprazole sulfone. This 
observation can be explained with the fact that less omeprazole was available 
to enter the CYP3A4-dependent metabolic pathway in subjects carrying the 
CYP2C19 variant. As a result, a very strong correlation of (r2=0.95) occurred 
between the AUCs measured for omeprazole and the sulfonated metabolite. 
No significant differences were observed in the AUCs of the 5-hydroxy 
metabolite between the CYP2C19 genotype groups.  
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Interestingly, a large interindividual variation in CYP2C19 activity was 
observed within the CYP2C19 wild-type group in contrast to the relatively 
similar low AUC values determined in the CYP2C19*17 group. 
 
4.2 PAPER II – INFLUENCE OF CYP2C19*17/*17 ON 
ESCITALOPRAM   PHARMACOKINETICS IN VIVO 
 
In a second approach we investigated how the genotype CYP2C19*17/17 
influences the metabolism of the CYP2C19 probe drug escitalopram 
compared to CYP2C19*1/*1. A sample size of six CYP2C19*17/*17 
subjects and twelve CYP2C19*1/*1 subjects was estimated to have 80% 
power to show a true difference in the AUC of 40% between the groups (as 
predicted from (Sim et al., 2006)). Eventually we were able to include 11 wt 
carriers and 5 homozygous CYP2C19*17 carriers into the study and treat 
them with 5 mg of escitalopram over one week. Steady state kinetics of the 
drug was analyzed on day 7 of treatment. 
The analysis focused on the determination of the pharmacokinetic 
characteristics of escitalopram and its main metabolite 
desmethylescitalopram. A 21% lower mean escitalopram AUC0-12 was 
observed in homozygous CYP2C19*17 carriers compared to the mean AUCs 
measured in CYP2C19 wild-type carriers. This observation was in agreement 
with the finding of faster metabolism towards the CYP2C19 probe drug 
omeprazole in CYP2C19*17/*17 carriers presented in paper I. The results 
obtained for escitalopram were, however, not statistically significant. 
Furthermore, no differences in the concentration-time curves of 
desmethylescitalopram were observed between the genotype groups. 
Interestingly, a low variability in the measured AUCs1-12 of escitalopram was 
observed within the CYP2C19*17/*17 group, compared to considerable 
higher interindividual differences within the CYP2C19 wild-type group.  
Subjects homozygous for CYP2C19*17/17 were thereby found within a low 
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escitalopram AUC value range. Similar observations were made for the 
omeprazole AUCs in paper I.   
Both observations are reflected in a relatively strong correlation (coefficient 
0.67) between escitalopram AUC1-12 values and the determined omeprazole 
AUCs∞.   
 
4.3    PAPER III AND IV – THE ROLE OF GATA-4 IN CYP2C19 AND 
CYP2C9 GENE EXPRESSION 
 
The initial hypothesis that GATA transcription factors could be possibly the 
responsible regulatory elements behind the modulating effect of the promoter 
variant CYP2C19*17 on CYP2C19 activity (which by (Sim et al., 2006) and 
in paper III was proven not to be the case) prompted us to the idea to further 
investigate the role of GATA proteins in the general transcriptional regulation 
of CYP2C19 and the sequence wise near relative CYP2C9 in paper III and IV.  
In luciferase assays we could show that several members of the GATA family 
are able to stimulate CYP2C9 and CYP2C19 promoter activities. In 
cotransfection experiments, the highest degrees of upregulation were 
observed for GATA-2 and GATA-4 (paper III, figures 2A/B and 3 A/B, paper 
IV, figures 2A and 2B).  
Bioinformatic analysis predicted two adjacent potential GATA-binding sites 
at position -165/-156 in the CYP2C19 promoter which is conserved in the 
CYP2C9 promoter at position -163/-154. Co-transfection experiments in 
HepG2 and Huh7 cells applying GATA constructs and several deletion 
constructs of different lengths derived from the CYP2C19 and CYP2C9 5’-
flanking regions narrowed the binding region of GATA down to the predicted 
loci (shown in paper III for the CYP2C19 promoter, figures 2A/B and 3A/B). 
To prove the functional importance of the predicted GATA binding sites for 
both genes we artificially changed the putative binding sites by site-directed 
mutagenesis and co-transfected the modulated CYP2C19 and CYP2C9 
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promoter constructs together with GATA-2 and GATA-4 expression plasmids 
into Huh7 and HepG2 cells. As shown in paper III, figure 2A/B and 3A/B, 
and paper IV figure 2A/B, the introduction of mutations resulted in a 
significant loss of GATA-dependent promoter stimulation in the case of both 
CYP2C19 and CYP2C9. This confirmed the significant role of the predicted 
response elements for a GATA-dependent transcriptional regulation. 
EMSAs using nuclear extracts from HepG2 and Huh7 cells revealed specific 
binding by GATA-4 and partly by GATA-6 to the oligonucleotides that 
carried the GATA binding sites of the CYP2C19 and CYP2C9 promoters. 
Specificity of binding was proven by successful supershifts with GATA-4- 
and GATA-6-specific antibodies (paper III figure 4, paper IV figure 3). 
To test whether GATA-proteins are associated with the predicted binding 
sites in the CYP2C9 and CYP2C19 promoters in intact cells we performed 
ChIP assays using genomic DNA from HepG2 cells and an antibody specific 
for the liver-enriched GATA family member GATA-4. Promoter fragments 
were amplified using one primer pair (paper IV) or two primer pairs (paper 
III) encompassing the putative GATA binding sites in question. As shown in 
paper III (figure 5), and in paper IV (figure 4), PCR products could be 
successfully generated matching the size of the promoter fragments, which 
carry the GATA binding sites when GATA-4 antibody was utilized. 
Furthermore, the control reactions with unspecific IgG antibodies led to a 
negative PCR output, thus proving the specificity of the experiment.  
 
GATA proteins are known to interact with the co-regulatory acting 
transcription factor family FOG (Friend of GATA), which contains two FOG 
proteins, FOG-1 and FOG-2. Especially FOG-2 has been proven to co-
regulate GATA-4 and to influence the transcription of its target genes. To 
test, whether FOG-2 influences a GATA-4-dependent regulation of CYP2C19 
and CYP2C9 gene expression, we performed luciferase gene reporter 
experiments where GATA-4 and FOG-2 were co-transfected and CYP2C9 or 
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CYP2C19 promoter activity was detected in Huh7 cells.  As shown in paper 
III on figure 6, and in paper IV on figure 5, GATA-4 alone upregulated both 
CYP2C19 and CYP2C9 promoter-driven luciferase expression as expected. 
Increasing amounts of co-transfected FOG-2 construct inhibited the observed 
GATA-4 dependent upregulation, proving the antagonistic effect of FOG-2 
on GATA-4 activity on both promoters. The co-transfection of an expression 
plasmid encoding a mutated FOG-2 variant, lacking the fragment coding for 
the GATA-interacting zinc finger domain, showed a significantly reduced 
inhibitory effect on GATA-4-dependent promoter stimulation.     
 
4.4  PAPER V AND VI – THE INFLUENCE OF ESTROGEN 
RECEPTOR ALPHA ON CYP2C19 AND CYP2C9 GENE 
EXPRESSION 
 
Both CYP2C9 and CYP2C19 activity are known to be inhibited by female 
sex steroids. The mechanisms how estradiol derivatives influence the enzyme 
activities are not yet fully understood. In Paper V and VI we tested whether 
ERα and ERβ and their ligands are putative modulators of CYP2C19 and 
CYP2C9 gene expression. 
Bioinformatic analysis of the CPY2C19 and CYP2C9 gene promoter revealed 
four putative ER DNA-binding half-sites at positions (-151/-147), (-1117/-
1113), (-1515/-1511), (-1611/-1607) and at positions (-1829/-1825), (-1557/-
1553), (-149/-145) and (-104/-100), respectively. To investigate whether these 
loci are targeted by ERα and/or ERβ EMSA analysis was performed. For each 
promoter region four different oligonucleotides, which comprised the putative 
ERE half sites and nuclear extracts from Huh7 and HepG2 cells were utilized. 
We could prove that ERα was capable of binding to ERE half sites (-151/-
147) and (-149/-145) within CYP2C19 promoter and CYP2C9 promoter, 
respectively, as confirmed by a positive supershift or a successful competition 
reaction of the generated binding complex with a specific antibody against 
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ERα (Paper V and VI, figure 2). ERβ did not bind to any of the putative ERE 
half sites within the 5´flanking region of CYP2C19 in EMSA experiments. 
To further confirm an interaction between ERα and CYP2C9 and CYP2C19 
gene promoter and to further elucidate the influence of ERα on CYP2C9 and 
CYP2C19 gene expression, we performed luciferase gene reporter assays. 
Cell experiments co-transfecting a plasmid carrying 1.6 kb or 0.5kb long 
fragments of CYP2C19 and CYP2C9 gene promoter, respectively, and an 
ERα expression vector revealed a dose-dependent inhibition of reporter 
luciferase activity upon cell treatment with 17β-estradiol in the case of 
CYP2C19 promoter and with 17α-ethinylestradiol in the case of both 
CYP2C19 and CYP2C9 promoter. The SERMs 4-hydroxytamoxifen and 
raloxifene did not influence CYP2C19 promoter activity but were able to 
slightly transactivate the CYP2C9 promoter. Using the approach of site-
directed mutagenesis we could confirm, that ERE half site (-151/-147) and (-
149/-145) are partly responsible for the ER-mediated modulatory effects on 
CYP2C19 and CYP2C9 gene expression observed. 
The inhibitory effect of estrogens on CYP2C19 and CYP2C9 gene expression 
was also confirmed in human hepatocytes. Here, the amount of detected 
CYP2C19 mRNA was significantly lower in cells treated with 17β-estradiol, 
when compared to cells treated with vehicle substance only (Paper V, figure 
5). In the case of CYP2C9 the inhibitory effect of ETE on CYP2C9 expression 
was significant and much more pronounced compared to the inhibitory effect 
of EE (paper VI, figure 6). 
ChIP experiments using Huh7 cells and an antibody specific for ERα 
confirmed in vivo binding of ERα to promoter fragments that comprise the 
identified functionally relevant ERE half-sites within both CYP2C19 and 
CYP2C9 promoter.  
As described in paper V, ETE and EE are also able to directly inhibit 
CYP2C19 enzyme activity. Assays using a stably transfected CYP2C19 
HEK-293 cell line and CYP2C19 enzyme activity measurements in 
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microsomes of insect cells overexpressing CYP2C19 showed, however, that 
the dosages of hormone needed for an effective direct inhibition were of 1 to 
2 magnitudes higher than the dosages required for an inhibitory effect on the 
gene promoter in luciferase gene reporter assays (Paper V, figure 7).    
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5 DISCUSSION 
 
5.1    THE INFLUENCE OF CYP2C19*17 ON DRUG  PHARMACO-        
KINETICS IN VIVO 
 
5.1.1 Omeprazole and Escitalopram 
Interindividual variability in the activity of drug metabolizing enzymes is a 
major cause for differences in drug exposure and, hence, a major contributor 
to variation in drug response (Rudberg et al., 2008). 
In case of the enzyme CYP2C19 especially the variants CYP2C19*2 and 
CY2C19*3 have been over a long time considered to be sufficient for 
prediction of the CYP2C19 phenotype. The discovery of the variant 
CYP2C19*17 and the postulation of a linkage to a lower systemic exposure 
towards the probe substrate omeprazole opened the possibility for a further 
explanation of the wide interindividual variability observed for CYP2C19 
probe drugs. Since then several studies have been published investigating the 
influence of CYP2C19*17 on the pharmacokinetics of several different 
CYP2C19 substrates (see also chapter 5.1.2)  
PPIs represent good probe drugs for CYP2C19 activity, as the drug group is 
of clinical importance and their pharmacokinetic characteristics, e.g. the area 
under the plasma concentration time curve (AUC), correlate well with the 
drug response which is well expressed in the measured levels of the 
intragastric pH, healing efficacy of peptic ulcer or severity of 
gastroesophageal reflux disease (Klotz, 2006).  
In our pilot study presented in paper I we could show that homozygously 
expressed CYP2C19*17 has a significant impact on omeprazole 
pharmacokinetics. The study was the first systematic approach investigating 
the impact on CYP2C19*17 on the in vivo pharmacokinetics of a CYP2C19 
probe drug. Since then several small studies addressing the same topic have 
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been published. One study included and compared CYP2C19 wild-type 
carriers and individuals heterozygous for CYP2C19*17 concerning the mean 
AUC0-24 levels for omeprazole and pantoprazole after both single dosing and 
multiple dosing. Despite a trend towards lower AUCs for heterozygous 
CYP2C19*17 carriers no significant differences between the genotype groups 
were observed (Hunfeld et al., 2008). Another study including a cohort of 
children came to similar results. Homozygous CYP2C19*17 carriers were, 
however, not investigated in either of these studies. These findings together 
with our findings support the hypothesis that a homozygous expression of 
CYP2C19*17 seems to bear greater impact on the omeprazole 
pharmacokinetics than a heterozygous expression. However, additional 
studies, ideally including larger populations, have to be performed to further 
elucidate the relevance of CYP2C19*17. Moreover, it would be desirable to 
investigate the influence of CYP2C19*17/*17 on the clinical outcome with 
PPIs by correlating the CYP2C19*17/*17 genotype with e.g. intragastric pH 
levels or the healing efficacy of peptic ulcer, such as already performed for 
the CYP2C19 PM genotype in the past (Kang et al., 2008; Saitoh et al., 2009) 
. 
The influence of CYP2C19*17/*17 on pharmacokinetics of citalopram or 
escitalopram is not comprehensively investigated yet. We did not observe a 
significant difference between escitalopram and N-desmethylescitalopram 
levels when comparing homozygous CYP2C19*1 and homozygous 
CYP2C19*17 carriers. Only one other study so far has addressed this question 
and has retrospectively investigated the influence of a heterozygous or 
homozygous expression of CYP2C19*17 on dose-adjusted escitalopram 
plasma levels in a pool of 166 depressive patients (Rudberg et al., 2008). This 
study detected 42% lower escitalopram mean plasma levels in 
CYP2C19*17/*17 carriers compared to wild-type carriers. While a positive 
aspect of the study of Rudberg et al. is that a high number of patients have 
taken the drug over a relatively long time frame, a weak point of this 
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investigation might be, however that the concentration measurements were 
made over a wide sampling-time window of 10-30h after the last dose. 
Moreover, the differences in escitalopram plasma concentrations were much 
more pronounced between homozygous PMs and CYP2C19 wild type 
carriers.  
In conclusion, further studies have to be performed in the future – ideally 
including more participants or patients than we were able in our pilot study - 
to clarify the importance of CYP2C19*17 in escitalopram metabolism.  
 
5.1.2 CYP2C19*17 and other CYP2C19 substrates 
Especially the PM allele CYP2C19*2 has been associated with reduced 
effectiveness of the antiplatelet prodrug clopidogrel, which is metabolically 
activated by both CYP2C19 and CYP3A4 (Hulot et al., 2006; Kim et al., 
2008; Shuldiner et al., 2009). The poorer response of PMs to clopidogrel is 
due to less extensive prodrug activation. Two studies, which investigated the 
role of CYP2C19*17 in platelet response upon clopidogrel treatment, could 
show that the CYP2C19*17 allele has a significant impact on the antiplatelet 
effect of clopidogrel that is connected to a higher risk for bleeding events due 
to increased prodrug activiation, as shown in a cohort of patients on 
clopidogrel-treatment for prevention of stent thrombosis (Sibbing et al., 
2010a; Sibbing et al., 2010b).   
The estrogen antagonist tamoxifen is mainly metabolized by CYP2D6, 
although other CYP enzymes, such as CYP2C19, are also involved in the 
formation of the two main metabolites 2- and 4-hydroxytamoxifen. Especially 
4-hydroxytamoxifen is an active metabolite of tamoxifen with a significantly 
higher therapeutic effect than the maternal substance. Interestingly, 
CYP2C19*17 has been associated with better tamoxifen response, as 
demonstrated by a lower risk of  relapse for CYP2C19*17 carrying breast 
cancer patients compared to EM or PM phenotype expressing patients 
(Schroth et al., 2007).  
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The antifungal drug voriconazole is extensively metabolized by CYP2C19 
and to a lesser extent by CYP3A4 and CYP2C9 (Theuretzbacher et al., 2006; 
Wang et al., 2009). In addition to strong and significant differences in 
pharmacokinetic key parameters between homozygous PMs carrying 
CYP2C19*2/*2 and CYP2C19*1/*1 carrying individuals, Wang et al. 
observed significant differences in the AUC0-24 of voriconazole in 
heterozygous CYP2C19*17 carriers compared to wild-type individuals. 
Homozygous expression of CYP2C19*17 was not investigated due to the fact 
that homozygous carriers of CYP2C19*17 were not detected in the included 
Chinese population. 
CYP2C19*17 has been also associated with a fast CYP2C19 dependent 
metabolism of the antidepressant imipramine and the antimalarial drug 
chlorproguanil. About 50% higher AUC0-24 values were observed for the 
chlorproguanil metabolite chlorcycloguanil in the CYP2C19*17 carrier group 
compared to wild type carrying individuals in a study, which included 43 
Gambians treated for malaria (Janha et al., 2009). In addition, about 30% 
lower imipramine steady state plasma concentration levels where measured in 
homozygous CYP2C19*17 allele carriers compared to wild type carrying 
individuals in a study that investigated 178 patients treated for depression 
(Schenk et al., 2010).  
It remains to be further elucidated in future studies to which extend the three 
latter findings are of clinical relevance.   
 
5.2 THE ROLE OF GATA PROTEINS IN THE EXPRESSION OF 
DRUG METABOLIZING ENZYMES  
 
In paper III and IV we have identified a functionally relevant double GATA 
binding site in the proximal area of both CYP2C19 and CYP2C9 gene 
promoters. We could show that this element can be transactivated by 
members of the GATA family and binds mainly the liver-abundant protein 
GATA-4 in liver-derived cell lines HepG2 or Huh7. A broad binding 
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potential of different GATA proteins to the same element is well in line with 
the fact that GATA proteins share high amino acid similarity within their 
double zinc finger domains, responsible for DNA interaction.  
 
In former times GATA family members have been mainly associated with 
their important regulatory role in the expression of genes either involved in 
the development of different blood cell lines (GATA-1 to GATA-3) or in the 
development of the heart and other endodermal derivatives (GATA-4 to 
GATA-6). An increasing number of publications have shown that GATA 
factors are also taking part in the regulation of cytochrome P450 enzymes and 
other xenobiotic metabolizing enzymes as well as drug transporters. CYP17, 
which is expressed in the adrenal cortex and which is involved in the cortisol 
biosynthesis, has been shown to be upregulated by GATA-6 in concert with 
the transcription factor specificity protein 1 (Sp1). Interestingly the 
stimulatory actions of GATA-6 on CYP17 promoter are based on a protein-
protein interaction with Sp1 rather than on a direct DNA binding. The 
expression of CYP19, an enzyme which is involved in estrogen biosynthesis, 
is influenced by GATA-4. Shadley et al. identified a far upstream enhancer in 
CYP2E1 5’-flanking region which is stimulated by GATA-4 (Shadley et al., 
2007). This aspect together with our findings supports the hypothesis that the 
spectrum of genes regulated by GATA factors is certainly greater then 
initially thought and investigated. It becomes more and more clear that GATA 
proteins play a role in the regulation of genes involved in the metabolism of 
endogenous and exogenous compounds. 
   
Many other transcription factors have been determined, which act in concert 
with GATA proteins. This feature has been especially well investigated for 
GATA-1 (Morceau et al., 2006) and GATA 4 (McBride et al., 2003; Temsah 
and Nemer, 2005). For the regulation of CYP2C19 and CYP2C9 promoter it 
can also be presumed that GATA-4 cooperates with other transcription 
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factors. Kawashima et al. experimentally proved the functional relevance of 
two DR-1 elements, which are able to bind the important liver enriched 
transcription factor HNF-4α and to transactivate CYP2C9 (Kawashima et al., 
2006). These sites are located in direct neighbourhood to our GATA binding 
sites identified in this thesis (figure 7). Furthermore, the functionally relevant 
ERE half site detected in CYP2C19 promoter (paper V) is also located 
directly next to the GATA binding sites. The hypothesis of a direct interaction 
between HNF-4a, ERα and GATA-4 has, however, to be experimentally 
proven.  
 
The functional relevance of GATA-4-dependent regulation of the CYP2C9 
and CYP2C19 promoters remains to be further investigated. It would be of  
Fig. 8: Functionally confirmed and putative transcription factor binding sites within CYP2C9  
and CYP2C19 promoters. The checked boxes show HNF-4 binding sites, which are, however, 
not functionally active. In red: newly identified and functionally active double GATA binding 
site in CYP2C9 and CYP2C19. In brown: Functionally confirmed ERα binding site in 
CYP2C19 which is conserved in CYP2C9. 
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interest, whether endogenous and exogenous substances including drugs 
influence the expression or binding capacity of GATA to both promoters.  
GATA factors are known to be targets for a range of signalling cascades 
(Temsah and Nemer, 2005). Further understanding of variation in the 
expression of chief regulators of CYP2C9 and CYP2C19, such as GATA 
proteins, may shed more light on the unsolved problem, why the enzymes 
CYP2C9 and CYP2C19 show such a wide interindividual range in gene 
expression, a fact that can only partly be explained by functionally relevant 
polymorphisms.   
 
It should also be taken into account that GATA transcription factors 
themselves are polymorphically expressed. Several variants seem to be of 
functional relevance as they have been associated with various pathological 
phenotypes (see table 2). Therefore, it can not be excluded that polymorphic 
expression of especially GATA-4 has an impact on gene expression of 
CYP2C9 or CYP2C19.  
 
5.3 THE ROLE OF ER ALPHA IN THE EXPRESSION OF DRUG 
METABOLIZING ENZYMES  
 
A significant inhibitory effect of oral contraceptives (most often comprising  
ethinylestradiol and levonogestrel) have been observed in several in vivo 
studies with various CYP2C19 substrates including omeprazole (Palovaara et 
al., 2003), proguanil, cycloguanil (McGready et al., 2003),  and carisoprodol 
(Bramness et al., 2005). The inhibitory effect is probably only mediated by 
the estradiol derivative as shown in an in vivo study using the CYP2C19 
probe drug omeprazole performed by Palovaara et al. (Palovaara et al., 
2003). For CYP2C9 not as many in vivo studies investigating the influence of 
estradiol derivatives on enzyme activity have been performed yet. Significant 
inhibitory effects of female sex steroids were, however, not only observed on 
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the metabolism of the CYP2C9 probe drug losartan. Estradiol derivatives 
have been shown to also significantly higher the anticoagulative effect of the 
CYP2C9 substrate warfarin in vivo (Sandberg et al., 2004; Zingone et al., 
2009). Especially the latter observation is of clinical importance as small 
alterations in warfarin concentrations can easily lead to bleeding 
complications.  
 
In our in vitro studies presented in paper V and VI we could show that ERα is 
able to bind to an ERE half-site located in the proximal part of the CYP2C19 
and CYP2C9 5’-flanking region and to suppress CYP2C19 and CYP2C9 
expression in a dose-dependent manner. This study provides evidence that 
inhibitory effects on CYP2C19 and CYP2C9 activity earlier observed with 
estradiol derivatives can be at least partly explained by this promoter-
dependent regulatory pathway. This hypothesis holds probably especially true 
for CYP2C19. The estrogen concentrations needed for the inhibition of 
CYP2C19 gene expression were 1 to 2 magnitudes lower than the 
concentrations needed for direct protein inhibition. Based on these results it is 
likely that estrogen-dependent inhibitory effects on CYP2C19 activity are 
rather transcription factor-mediated than induced by direct competitive 
inhibition at the active site of CYP2C19. 
The ERE half-sites detected at positions (-151/-147) and (-149/-145) in 
CYP2C19 and CYP2C9 promoter match exactly one half of the palindromic 
ERE consensus sequence. Several in vitro studies could show that a binding 
of ERα or ERβ to a half site of the ERE consensus sequence is sometimes 
sufficient to mediate an ER-dependent response of the target promoter (Chen 
et al., 2008; Kimura et al., 2008). An important observation is, however, that 
mutations introduced into the functionally relevant ER-binding element led to 
only a partial reconstitution especially of CYP2C19 promoter activity. 
Therefore, it can not be excluded that other ER-dependent pathways are 
involved in the regulation of the CYP2C19 gene expression. It is, for example, 
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known that ERα often mediates its effects via protein-protein interactions. 
Furthermore, ERα influences the expression of other transcription factors, 
such as AP-1, SP-1 or NF-κB, by stabilizing their DNA-binding and/or 
recruiting co-activators to the binding complex (Higashi et al., 2007). 
An ERα-dependent regulation of CYP2C19 and CYP2C9 gene expression is 
well in line with the fact that ERα and both CYP enzymes are abundantly 
expressed in liver (Rodriguez-Antona and Ingelman-Sundberg, 2006; Higashi 
et al., 2007). A comparative sequence analysis of the proximal CYP2C9 and 
CYP2C19 gene promoter revealed that the detected functionally relevant ERE 
half sites are located within a conserved region which is very similarly 
composed in CYP2C9 and CYP2C19. In addition to CYP2C9 and CYP2C19, 
genes encoding other CYP enzymes, which are expressed in estrogen related 
tissues such as mammary, uterus and ovary, have been shown to be regulated 
by ERα. This includes CYP2A6 (Higashi et al., 2007) and CYP1B1 (Tsuchiya 
et al., 2004). In these cases ERα-dependent regulation is as well mediated by 
the classical pathway recruiting (complete) ERE consensus sequences.  
Interestingly, only the CYP2C9 promoter but not the CYP2C19 promoter is 
(weakly) transactivated by SERMS. It is, however, questionable how 
important the observed promoter mediated induction is, as one study showed 
that tamoxifen significantly inhibits CYP2C9 activity in vivo (Boruban et al., 
2006) . Therefore it can not be excluded that tamoxifen exhibits in parallel an 
inhibitory effect by other not yet investigated mechanisms, which has a 
stronger impact on enzyme activity than the observed promoter mediated 
effects. 
Especially CYP2C19 expression is ERα and estradiol dependently regulated. 
What could be the (patho)physiological importance for this observation? 
Similarly to CYP1B1, which is one of the key enzymes in estrogen 
metabolism, CYP2C19 is also playing a role in the transformation of 
estrogens. Thus, it can be assumed that both enzymes play a role in general 
estrogen homeostasis. It can not be excluded that variability in estrogen 
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dependent regulation of estrogen metabolizing enzymes like CYP1B1 or 
CYP2C19 influence hormone dependent events such as estrogen-dependent 
carcinogenesis. 
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6  THESIS SUMMARY AND CONCLUSIONS 
 
6.1 CYP2C19*17 AND ITS INFLUENCE ON CYP2C19 DEPENDENT 
METABOLISM IN VIVO 
 
The main results obtained in the in vivo studies investigating the influence of 
the promoter SNP CYP2C19*17 on omeprazole and escitalopram metabolism 
and the main conclusions to be drawn can be summarized as follows: 
 
• CYP2C19*17/*17 has a significant influence on omeprazole 
pharmacokinetics in vivo 
• CYP2C19*17/*17 has to be further investigated concerning its impact on 
therapy efficacy with omeprazole, ideally in large panel studies 
considering a measurement of therapy outcome parameters 
• The impact of  CYP2C19*17/*17 on escitalopram metabolism is not as 
strong as on omeprazole pharmacokinetics and seems not to be significant 
• In both pilot studies a trend towards lower AUCs for both omeprazole and 
escitalopram were observed. The AUC values were condensed within 
small value intervals. This leads to the hypothesis that regulatory 
elements, which bind to the SNP locus in CYP2C19 promoter seem to 
have a strong impact towards a high and uniform expression of 
CYP2C19. It still remains to be investigated which transcription factor(s) 
are responsible for this observed phenomenon 
 
6.2 THE IMPACT OF THE GATA TRANSCRIPTION FACTOR     
FAMILY GATA ON CYP2C19 AND CYP2C9 EXPRESSION 
 
Conclusions to be drawn and future perspectives arising from the studies 
investigating the influence of GATA factors on transcriptional regulation of 
CYP2C9 and CYP2C19 can be summarized as follows: 
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• Both CYP2C19 and CYP2C9 promoters are significantly transactivated by 
GATA factors through a conserved double GATA binding site.  
• The strength of inducibility of both promoters by GATA factors leads to 
the hypothesis that GATA seems to play an important role in the 
endogenous constitutive expression of CYP2C9 and CYP2C19.  
• The binding occurs within promoter areas of CYP2C9 and CYP2C19, 
which are densely targeted by other transcription factors.  
• It remains to be investigated how GATA factors are interacting with other 
transcription factors on the transcriptional regulation of CYP2C genes that 
bind especially in the neighborhood of the detected GATA binding sites. 
Putative cooperators include especially the regulatory proteins HNF4α, 
ERα, cEBP and HNF-3γ. 
• It would be worth to further investigate, whether GATA expression itself 
is influenced by xenobiotic agents and endogenous substrates via e.g. 
nuclear factors like PXR or CAR, thus being able to mediate for example 
drug dependent effects on CYP2C9 and CYP2C19 mRNA and protein 
expression. This would perhaps also further explain the large 
interindividual differences observed for CYP2C19 and CYP2C9 activity. 
 
6.3  THE IMPACT OF ER ΑLPHA ON CYP2C19 AND CYP2C9 
EXPRESSION 
 
The following conclusions can be drawn from the investigation: 
 
• ERα is able to mediate an estradiol derivative dependent inhibition on 
both CYP2C9 and CYP2C19 gene expression via a conserved ERE half 
site within CYP2C9 and CYP2C19 gene promoter.  
• The promoter mediated inhibition of CYP2C19 by estrogens takes place at 
significant lower estrogen concentrations compared to the estrogen 
concentrations needed for a direct enzyme inhibition. This finding leads to 
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the conclusion that the known inhibitory effect of estrogens on CYP2C19 
in vivo is likely to be promoter mediated rather than through direct 
inhibition of the active center of CYP2C19.  
• The newly detected ERE half site is likely to be not the only binding site 
of ERα. It can be assumed that other (non classical) pathways are also 
taking part in the promoter mediated regulation of especially CYP2C19 
expression. This has however to be experimentally proven in the future. 
• Whereas both CYP2C9 and CYP2C19 gene expression appears to be 
significantly inhibited by especially α-ethinylestradiol, only CYP2C9 
promoter turns out to be weakly transactivated by SERMS, such as 4-
hydroxy-tamoxifen. This observed effect is, however, likely to be 
overwhelmed by in parallel occurring inhibitory effects of SERMS on 
CYP2C9 activity, which may be mediated by other mechanisms.  
 
 Acknowledgements  
 
 54
6   ACKNOWLEDGEMENTS 
 
My stay in Stockholm has been an exciting and instructive journey. I have been 
lucky enough to work at an extraordinary institute and department together with 
fabulous colleagues, to make new friends, to learn an additional foreign language and 
last but not least to get to know an impressive and beautiful country. What can you 
expect more from your PhD studies? 
First of all I would like to thank my main supervisor Professor Dr. Magnus 
Ingelman-Sundberg. I will always be truly grateful for having had the opportunity 
to work in your team and for your continuous and tremendous support, regardless of 
whether it concerned my PhD studies, or my professional development in Clinical 
Pharmacology and Bioinformatics. Thank you for your help and understanding in 
every scientific and personal step that I wanted to climb! ETT STORT, STORT 
TACK FÖR ALLT! 
To my co-supervisor Docent Dr. Souren Mkrtchian: Thank you so much for 
teaching me science and for always having an open ear for scientific questions  – our 
scientific discussions helped me enormously to get through long hours of manuscript 
writing. It has been a real pleasure to work with and learn from you!    
To my co-supervisor Docent Dr. Erik Eliasson, as well as to Professor Dr. Leif 
Bertilsson and to Dr. Staffan Rosenborg: Thank you for our close and productive 
collaboration during the development and execution of the clinical trials. The road 
from the initialization to the end of the studies may have been long, yet with you it 
turned out to be exciting and successful.  
Thank you also to Docent Dr. Inger Johansson and to Margareta Porsmyr-
Palmertz for helping me to take all bureaucratic hurdles during my “PhD final 
spurt”. 
A special and big THANK YOU to Dr. Isa Cavaco: It was so much fun and a real 
pleasure to work with you in the lab and to implement so many different projects 
together! Thanks for your enthusiasm, support and effort during all these years!  
Many, many thanks also to Dr. Rasmus Steen Pedersen, for all your aid in the lab 
and your efficient teamwork during your stay in Stockholm!  
Dr. Yvonne Hofmann, you are not only a great scientist but also a great friend. 
Thank you for your assistance and advice in the lab and for many nice afternoons 
with you, Knuth and your children in Stockholm and Berlin. I will always remember 
our motto: “Det löser sig!”  
Dr. Sarah C. Sim, I thank you for briefing me on the CYP2C19*17 story and for 
your support especially during my first weeks/months in the lab. 
Dr. Alvin Gomez, you have been a true friend and wonderful office mate during my 
whole time in Stockholm! I am grateful to have met you and to have experienced all 
kinds of cultural events with you. You are not only a close friend but also the best 
singer among all scientists I have met so far. 
                                                                                                         CYP2C19 and CYP2C9: 
                    New aspects of pharmacogenetics and transcriptional regulation 
 
 55
I thank Dr. Jana Nekvindová, Dr. Mike Baldwin and Anna Persson M.Sc. for 
productive collaborations.  
Furthermore, I direct a big thank you to the whole team of the Department of 
Clinical Pharmacology around Professor Dr. Anders Rane at Karolinska 
Hospital and to the team from the Karolinska Trial Alliance (KTA) around 
Docent Dr. Pierre Lafolie and Eva-Lena Forsberg. It was fantastic to finish my 
specialization in Clinical Pharmacology at your department. It has been an exciting 
time for me, I learned a lot and I enjoyed it very much. Tack för allt! 
Many thanks to Professor Dr. Gerd Kullak-Ublick, for giving me the opportunity 
to become part of his team in Zurich and for giving me the space and backing to 
finish my thesis writing, as well as to Docent Dr. Jyrki Eloranta for his scientific 
support during my time in Zurich and for keeping a final critical check on my thesis.   
I would like to thank my office mates Alvin, Yvonne, Isa, Åsa, Rasmus, Ylva, 
Susanne L, Sandra and Sun for filling our office with so much laughter and such a 
nice and comfortable atmosphere. 
Thanks also to the past master students I worked with: Sabrina Burkhardt, Begüm 
Yurdakök, Ellie Landman, Rebecca Axelsson and Erik Alzén. It has been real fun 
to work with all of you. 
To all other past and present members in the MIS lab: Sussi, Susanne A, Christina, 
Maria, Pernilla, Monika, Linn, Louise, Etienne, Marika, Hira, Masaja, Ernest, 
Frank, Kristian, Angelica, Jue, Marja and Christelle, thanks for making the daily 
lab work so easy and enjoyable. 
Many, many thanks to my friends Dr. Pascal Dammeyer and Dr. Dr. Linda 
Meyer! I feel very fortunate to have met you both in Stockholm! Thank you for all 
the nice moments we shared during our stay in Sweden and will hopefully share in 
the future – despite the fact that we all live in different countries now - and thank you 
for all the laughter and fun which make life so much richer.  
 
My biggest and deepest THANK YOU goes to my family - Mama, Papa, 
and my sisters Adina and Miriam: I know that I would not be where I am 
now, without your love, endless support and your belief in me. I am deeply 
grateful for having you. You are the most important for me in my life. Ich 
hab’ Euch sehr, sehr lieb! 
 
 
 References  
 
 56
REFERENCES 
 
Aktories K and Forth W (2009) Allgemeine und spezielle Pharmakologie und Toxikologie für 
Studenten der Medizin, Veterinärmedizin, Pharmazie, Chemie und Biologie sowie 
für Ärzte, Tierärzte und Apotheker. Elsevier, München. 
Arefayene M, Skaar TC, Zhao X, Rae JM, Tanus-Santos JE, Brinkmann U, Brehm I, Salat U, 
Nguyen A, Desta Z and Flockhart DA (2003) Sequence diversity and functional 
characterization of the 5'-regulatory region of human CYP2C19. Pharmacogenetics 
13:199-206. 
Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J and Nilsson S (1998) Differential 
response of estrogen receptor alpha and estrogen receptor beta to partial estrogen 
agonists/antagonists. Mol Pharmacol 54:105-112. 
Bertilsson L (1995) Geographical/interracial differences in polymorphic drug oxidation. 
Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin 
Pharmacokinet 29:192-209. 
Boron WF (2009) Medical physiology a cellular and molecular approach. Saunders/Elsevier, 
Philadelphia, PA. 
Bort R, Gomez-Lechon MJ, Castell JV and Jover R (2004) Role of hepatocyte nuclear factor 
3 gamma in the expression of human CYP2C genes. Arch Biochem Biophys 426:63-
72. 
Boruban MC, Yasar U, Babaoglu MO, Sencan O and Bozkurt A (2006) Tamoxifen inhibits 
cytochrome P450 2C9 activity in breast cancer patients. J Chemother 18:421-424. 
Bossard P and Zaret KS (1998) GATA transcription factors as potentiators of gut endoderm 
differentiation. Development 125:4909-4917. 
Bramness JG, Skurtveit S, Gulliksen M, Breilid H, Steen VM and Morland J (2005) The 
CYP2C19 genotype and the use of oral contraceptives influence the 
pharmacokinetics of carisoprodol in healthy human subjects. Eur J Clin Pharmacol 
61:499-506. 
Brewer A and Pizzey J (2006) GATA factors in vertebrate heart development and disease. 
Expert Rev Mol Med 8:1-20. 
Cai Z, Kwintkiewicz J, Young ME and Stocco C (2007) Prostaglandin E2 increases cyp19 
expression in rat granulosa cells: implication of GATA-4. Mol Cell Endocrinol 
263:181-189. 
Chang M, Dahl ML, Tybring G, Gotharson E and Bertilsson L (1995) Use of omeprazole as a 
probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-
mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 
5:358-363. 
Chen XN, Zhu H, Meng QY and Zhou JN (2008) Estrogen receptor-alpha and -beta regulate 
the human corticotropin-releasing hormone gene through similar pathways. Brain 
Res 1223:1-10. 
Chen Y, Ferguson SS, Negishi M and Goldstein JA (2003) Identification of constitutive 
androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 
promoter. Mol Pharmacol 64:316-324. 
                                                                                                         CYP2C19 and CYP2C9: 
                    New aspects of pharmacogenetics and transcriptional regulation 
 
 57
Chen Y, Ferguson SS, Negishi M and Goldstein JA (2004) Induction of human CYP2C9 by 
rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J 
Pharmacol Exp Ther 308:495-501. 
Chen Y, Kissling G, Negishi M and Goldstein JA (2005) The nuclear receptors constitutive 
androstane receptor and pregnane X receptor cross-talk with hepatic nuclear factor 
4alpha to synergistically activate the human CYP2C9 promoter. J Pharmacol Exp 
Ther 314:1125-1133. 
Crispino JD, Lodish MB, Thurberg BL, Litovsky SH, Collins T, Molkentin JD and Orkin SH 
(2001) Proper coronary vascular development and heart morphogenesis depend on 
interaction of GATA-4 with FOG cofactors. Genes Dev 15:839-844. 
Dame C, Sola MC, Lim KC, Leach KM, Fandrey J, Ma Y, Knopfle G, Engel JD and Bungert 
J (2004) Hepatic erythropoietin gene regulation by GATA-4. J Biol Chem 279:2955-
2961. 
de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA and Goldstein JA (1994) 
The major genetic defect responsible for the polymorphism of S-mephenytoin 
metabolism in humans. J Biol Chem 269:15419-15422. 
Delozier TC, Kissling GE, Coulter SJ, Dai D, Foley JF, Bradbury JA, Murphy E, Steenbergen 
C, Zeldin DC and Goldstein JA (2007) Detection of human CYP2C8, CYP2C9, and 
CYP2J2 in cardiovascular tissues. Drug Metab Dispos 35:682-688. 
Denson LA, McClure MH, Bogue CW, Karpen SJ and Jacobs HC (2000) HNF3beta and 
GATA-4 transactivate the liver-enriched homeobox gene, Hex. Gene 246:311-320. 
Desta Z, Zhao X, Shin JG and Flockhart DA (2002) Clinical significance of the cytochrome 
P450 2C19 genetic polymorphism. Clin Pharmacokinet 41:913-958. 
Drocourt L, Ourlin JC, Pascussi JM, Maurel P and Vilarem MJ (2002) Expression of 
CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in 
primary human hepatocytes. J Biol Chem 277:25125-25132. 
Ferguson SS, LeCluyse EL, Negishi M and Goldstein JA (2002) Regulation of human 
CYP2C9 by the constitutive androstane receptor: discovery of a new distal binding 
site. Mol Pharmacol 62:737-746. 
Fleming I (2001) Cytochrome p450 and vascular homeostasis. Circ Res 89:753-762. 
Fleming I (2008) Vascular cytochrome p450 enzymes: physiology and pathophysiology. 
Trends Cardiovasc Med 18:20-25. 
Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, Hanai H, Kubota T, 
Ishizaki T and Kaneko E (1998) Effect of genetic differences in omeprazole 
metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann 
Intern Med 129:1027-1030. 
Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A and Ishizaki T (2005) Influence of 
CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based 
therapies. Drug Metab Pharmacokinet 20:153-167. 
Gage BF and Lesko LJ (2008) Pharmacogenetics of warfarin: regulatory, scientific, and 
clinical issues. J Thromb Thrombolysis 25:45-51. 
Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, Daujat M, Waechter F, Fabre JM, Carrere 
N and Maurel P (2001) Induction of CYP2C genes in human hepatocytes in primary 
culture. Drug Metab Dispos 29:242-251. 
 
 References  
 
 58
Hagg S, Spigset O and Dahlqvist R (2001) Influence of gender and oral contraceptives on 
CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 51:169-
173. 
Hall JM and McDonnell DP (2005) Coregulators in nuclear estrogen receptor action: from 
concept to therapeutic targeting. Mol Interv 5:343-357. 
Herrlin K, Massele AY, Rimoy G, Alm C, Rais M, Ericsson O, Bertilsson L and Gustafsson 
LL (2000) Slow chloroguanide metabolism in Tanzanians compared with white 
subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to 
genotype. Clin Pharmacol Ther 68:189-198. 
Herrlin K, Yasui-Furukori N, Tybring G, Widen J, Gustafsson LL and Bertilsson L (2003) 
Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of 
healthy Swedes. Br J Clin Pharmacol 56:415-421. 
Higashi E, Fukami T, Itoh M, Kyo S, Inoue M, Yokoi T and Nakajima M (2007) Human 
CYP2A6 is induced by estrogen via estrogen receptor. Drug Metab Dispos 35:1935-
1941. 
Hirai M, Ono K, Morimoto T, Kawamura T, Wada H, Kita T and Hasegawa K (2004) FOG-2 
competes with GATA-4 for transcriptional coactivator p300 and represses 
hypertrophic responses in cardiac myocytes. J Biol Chem 279:37640-37650. 
Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P and 
Gaussem P (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a 
major determinant of clopidogrel responsiveness in healthy subjects. Blood 
108:2244-2247. 
Hunfeld NG, Mathot RA, Touw DJ, van Schaik RH, Mulder PG, Franck PF, Kuipers EJ and 
Geus WP (2008) Effect of CYP2C19*2 and *17 mutations on pharmacodynamics 
and kinetics of proton pump inhibitors in Caucasians. Br J Clin Pharmacol 65:752-
760. 
Ibeanu GC and Goldstein JA (1995) Transcriptional regulation of human CYP2C genes: 
functional comparison of CYP2C9 and CYP2C18 promoter regions. Biochemistry 
34:8028-8036. 
Ingelman-Sundberg M (2004a) Human drug metabolising cytochrome P450 enzymes: 
properties and polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 369:89-
104. 
Ingelman-Sundberg M (2004b) Pharmacogenetics of cytochrome P450 and its applications in 
drug therapy: the past, present and future. Trends Pharmacol Sci 25:193-200. 
Ingelman-Sundberg M, Sim SC, Gomez A and Rodriguez-Antona C (2007) Influence of 
cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, 
pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496-526. 
Janha RE, Sisay-Joof F, Hamid-Adiamoh M, Worwui A, Chapman HL, Opara H, Dunyo S, 
Milligan P, Rockett K, Winstanley P, Pirmohamed M, Miller AK, Conway DJ and 
Walton RT (2009) Effects of genetic variation at the CYP2C19/CYP2C9 locus on 
pharmacokinetics of chlorcycloguanil in adult Gambians. Pharmacogenomics 
10:1423-1431. 
Jover R, Bort R, Gomez-Lechon MJ and Castell JV (2001) Cytochrome P450 regulation by 
hepatocyte nuclear factor 4 in human hepatocytes: a study using adenovirus-
mediated antisense targeting. Hepatology 33:668-675. 
                                                                                                         CYP2C19 and CYP2C9: 
                    New aspects of pharmacogenetics and transcriptional regulation 
 
 59
Jurima-Romet M, Goldstein JA, LeBelle M, Aubin RA, Foster BC, Walop W and Rode A 
(1996) CYP2C19 genotyping and associated mephenytoin hydroxylation 
polymorphism in a Canadian Inuit population. Pharmacogenetics 6:329-339. 
Jurima M, Inaba T and Kalow W (1985) Mephenytoin hydroxylase activity in human liver: 
inhibition by steroids. Drug Metab Dispos 13:746-749. 
Kamali F and Wynne H (2010) Pharmacogenetics of warfarin. Annu Rev Med 61:63-75. 
Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, Lin SC, Heyman RA, Rose 
DW, Glass CK and Rosenfeld MG (1996) A CBP integrator complex mediates 
transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85:403-414. 
Kang JM, Kim N, Lee DH, Park YS, Kim JS, Chang IJ, Song IS and Jung HC (2008) Effect 
of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori 
infection by 7-day triple therapy with regular proton pump inhibitor dosage. J 
Gastroenterol Hepatol 23:1287-1291. 
Kang YK, Guermah M, Yuan CX and Roeder RG (2002) The TRAP/Mediator coactivator 
complex interacts directly with estrogen receptors alpha and beta through the 
TRAP220 subunit and directly enhances estrogen receptor function in vitro. Proc 
Natl Acad Sci U S A 99:2642-2647. 
Kawashima S, Kobayashi K, Takama K, Higuchi T, Furihata T, Hosokawa M and Chiba K 
(2006) Involvement of hepatocyte nuclear factor 4alpha in the different expression 
level between CYP2C9 and CYP2C19 in the human liver. Drug Metab Dispos 
34:1012-1018. 
Kim KA, Park PW, Hong SJ and Park JY (2008) The effect of CYP2C19 polymorphism on 
the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism 
for clopidogrel resistance. Clin Pharmacol Ther 84:236-242. 
Kimura N, Takamatsu N, Yaoita Y and Osamura RY (2008) Identification of transcriptional 
regulatory elements in the human somatostatin receptor sst2 promoter and regions 
including estrogen response element half-site for estrogen activation. J Mol 
Endocrinol 40:75-91. 
Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I and Brockmoller J (2004) 
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic 
variations to the phenotype of drug response. Mol Psychiatry 9:442-473. 
Klose TS, Blaisdell JA and Goldstein JA (1999) Gene structure of CYP2C8 and extrahepatic 
distribution of the human CYP2Cs. J Biochem Mol Toxicol 13:289-295. 
Klotz U (2006) Clinical impact of CYP2C19 polymorphism on the action of proton pump 
inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 44:297-302. 
Klotz U, Schwab M and Treiber G (2004) CYP2C19 polymorphism and proton pump 
inhibitors. Basic Clin Pharmacol Toxicol 95:2-8. 
Laine K, Palovaara S, Tapanainen P and Manninen P (1999) Plasma tacrine concentrations 
are significantly increased by concomitant hormone replacement therapy. Clin 
Pharmacol Ther 66:602-608. 
Laine K, Tybring G and Bertilsson L (2000) No sex-related differences but significant 
inhibition by oral contraceptives of CYP2C19 activity as measured by the probe 
drugs mephenytoin and omeprazole in healthy Swedish white subjects. Clin 
Pharmacol Ther 68:151-159. 
 
 References  
 
 60
Laine K, Yasar U, Widen J and Tybring G (2003) A screening study on the liability of eight 
different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human 
liver microsomes. Pharmacol Toxicol 93:77-81. 
Lapple F, von Richter O, Fromm MF, Richter T, Thon KP, Wisser H, Griese EU, Eichelbaum 
M and Kivisto KT (2003) Differential expression and function of CYP2C isoforms 
in human intestine and liver. Pharmacogenetics 13:565-575. 
Lu JR, McKinsey TA, Xu H, Wang DZ, Richardson JA and Olson EN (1999) FOG-2, a heart- 
and brain-enriched cofactor for GATA transcription factors. Mol Cell Biol 19:4495-
4502. 
Martinez-Jimenez CP, Castell JV, Gomez-Lechon MJ and Jover R (2006) Transcriptional 
activation of CYP2C9, CYP1A1, and CYP1A2 by hepatocyte nuclear factor 4alpha 
requires coactivators peroxisomal proliferator activated receptor-gamma coactivator 
1alpha and steroid receptor coactivator 1. Mol Pharmacol 70:1681-1692. 
Masimirembwa C, Bertilsson L, Johansson I, Hasler JA and Ingelman-Sundberg M (1995) 
Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 
2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 57:656-661. 
McBride K, Charron F, Lefebvre C and Nemer M (2003) Interaction with GATA 
transcription factors provides a mechanism for cell-specific effects of c-Fos. 
Oncogene 22:8403-8412. 
McDevitt MA, Glidewell-Kenney C, Jimenez MA, Ahearn PC, Weiss J, Jameson JL and 
Levine JE (2008) New insights into the classical and non-classical actions of 
estrogen: evidence from estrogen receptor knock-out and knock-in mice. Mol Cell 
Endocrinol 290:24-30. 
McDonnell DP and Norris JD (2002) Connections and regulation of the human estrogen 
receptor. Science 296:1642-1644. 
McGready R, Stepniewska K, Seaton E, Cho T, Cho D, Ginsberg A, Edstein MD, Ashley E, 
Looareesuwan S, White NJ and Nosten F (2003) Pregnancy and use of oral 
contraceptives reduces the biotransformation of proguanil to cycloguanil. Eur J Clin 
Pharmacol 59:553-557. 
Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, 
Macias W, Braunwald E and Sabatine MS (2009) Cytochrome p-450 
polymorphisms and response to clopidogrel. N Engl J Med 360:354-362. 
Milne RJ and Goa KL (1991) Citalopram. A review of its pharmacodynamic and 
pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 
41:450-477. 
Miners JO and Birkett DJ (1998) Cytochrome P4502C9: an enzyme of major importance in 
human drug metabolism. Br J Clin Pharmacol 45:525-538. 
Morceau F, Schnekenburger M, Blasius R, Buck I, Dicato M and Diederich M (2006) Tumor 
necrosis factor alpha inhibits aclacinomycin A-induced erythroid differentiation of 
K562 cells via GATA-1. Cancer Lett 240:203-212. 
Morrisey EE, Ip HS, Tang Z and Parmacek MS (1997) GATA-4 activates transcription via 
two novel domains that are conserved within the GATA-4/5/6 subfamily. J Biol 
Chem 272:8515-8524. 
Nebert DW (1999) Pharmacogenetics and pharmacogenomics: why is this relevant to the 
clinical geneticist? Clin Genet 56:247-258. 
                                                                                                         CYP2C19 and CYP2C9: 
                    New aspects of pharmacogenetics and transcriptional regulation 
 
 61
Ohneda K and Yamamoto M (2002) Roles of hematopoietic transcription factors GATA-1 
and GATA-2 in the development of red blood cell lineage. Acta Haematol 108:237-
245. 
Palovaara S, Tybring G and Laine K (2003) The effect of ethinyloestradiol and levonorgestrel 
on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects. Br 
J Clin Pharmacol 56:232-237. 
Peterkin T, Gibson A, Loose M and Patient R (2005) The roles of GATA-4, -5 and -6 in 
vertebrate heart development. Semin Cell Dev Biol 16:83-94. 
Peterkin T, Gibson A and Patient R (2003) GATA-6 maintains BMP-4 and Nkx2 expression 
during cardiomyocyte precursor maturation. EMBO J 22:4260-4273. 
Peyvandi F, Spreafico M, Siboni SM, Moia M and Mannucci PM (2004) CYP2C9 genotypes 
and dose requirements during the induction phase of oral anticoagulant therapy. Clin 
Pharmacol Ther 75:198-203. 
Rana R, Chen Y, Ferguson SS, Kissling GE, Surapureddi S and Goldstein JA (2010) 
Hepatocyte nuclear factor 4{alpha} regulates rifampicin-mediated induction of 
CYP2C genes in primary cultures of human hepatocytes. Drug Metab Dispos 
38:591-599. 
Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF and Korzekwa KR (1994) Impaired (S)-
warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. 
Pharmacogenetics 4:39-42. 
Roche AE, Bassett BJ, Samant SA, Hong W, Blobel GA and Svensson EC (2008) The zinc 
finger and C-terminal domains of MTA proteins are required for FOG-2-mediated 
transcriptional repression via the NuRD complex. J Mol Cell Cardiol 44:352-360. 
Rodrigues AD and Lu P (2004) Is 17alpha-ethinyl estradiol an inhibitor of cytochrome P450 
2C19? Drug Metab Dispos 32:364-365. 
Rodriguez-Antona C and Ingelman-Sundberg M (2006) Cytochrome P450 pharmacogenetics 
and cancer. Oncogene 25:1679-1691. 
Roh HK, Dahl ML, Tybring G, Yamada H, Cha YN and Bertilsson L (1996) CYP2C19 
genotype and phenotype determined by omeprazole in a Korean population. 
Pharmacogenetics 6:547-551. 
Rudberg I, Mohebi B, Hermann M, Refsum H and Molden E (2008) Impact of the ultrarapid 
CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. 
Clin Pharmacol Ther 83:322-327. 
Sagar M, Seensalu R, Tybring G, Dahl ML and Bertilsson L (1998) CYP2C19 genotype and 
phenotype determined with omeprazole in patients with acid-related disorders with 
and without Helicobacter pylori infection. Scand J Gastroenterol 33:1034-1038. 
Saitoh T, Otsuka H, Kawasaki T, Endo H, Iga D, Tomimatsu M, Fukushima Y, Katsube T, 
Ogawa K and Otsuka K (2009) Influences of CYP2C19 polymorphism on 
recurrence of reflux esophagitis during proton pump inhibitor maintenance therapy. 
Hepatogastroenterology 56:703-706. 
Sandberg M, Johansson I, Christensen M, Rane A and Eliasson E (2004) The impact of 
CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype. 
Drug Metab Dispos 32:484-489. 
Schenk PW, van Vliet M, Mathot RA, van Gelder T, Vulto AG, van Fessem MA, Verploegh-
Van Rij S, Lindemans J, Bruijn JA and van Schaik RH (2010) The CYP2C19*17 
 
 References  
 
 62
genotype is associated with lower imipramine plasma concentrations in a large group 
of depressed patients. Pharmacogenomics J 10:219-225. 
Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, Simon W, 
Eichelbaum M and Brauch H (2007) Breast cancer treatment outcome with adjuvant 
tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 
25:5187-5193. 
Schwab M, Klotz U, Hofmann U, Schaeffeler E, Leodolter A, Malfertheiner P and Treiber G 
(2005) Esomeprazole-induced healing of gastroesophageal reflux disease is 
unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic 
data. Clin Pharmacol Ther 78:627-634. 
Schwab M, Schaeffeler E, Klotz U and Treiber G (2004) CYP2C19 polymorphism is a major 
predictor of treatment failure in white patients by use of lansoprazole-based 
quadruple therapy for eradication of Helicobacter pylori. Clin Pharmacol Ther 
76:201-209. 
Seeringer A and Kirchheiner J (2008) Pharmacogenetics-guided dose modifications of 
antidepressants. Clin Lab Med 28:619-626. 
Shadley JD, Divakaran K, Munson K, Hines RN, Douglas K and McCarver DG (2007) 
Identification and functional analysis of a novel human CYP2E1 far upstream 
enhancer. Mol Pharmacol 71:1630-1639. 
Shi S and Klotz U (2008) Proton pump inhibitors: an update of their clinical use and 
pharmacokinetics. Eur J Clin Pharmacol 64:935-951. 
Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, 
Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, 
Herzog W and Gurbel PA (2009) Association of cytochrome P450 2C19 genotype 
with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 
302:849-857. 
Sibbing D, Gebhard D, Koch W, Braun S, Stegherr J, Morath T, von Beckerath N, Mehilli J, 
Schomig A, Schuster T and Kastrati A (2010a) Isolated and interactive impact of 
common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel 
therapy. J Thromb Haemost. 
Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Morath T, Schomig A, von 
Beckerath N and Kastrati A (2010b) Cytochrome 2C19*17 allelic variant, platelet 
aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients 
with coronary stent placement. Circulation 121:512-518. 
Sim SC and Ingelman-Sundberg M (2006) The human cytochrome P450 Allele 
Nomenclature Committee Web site: submission criteria, procedures, and objectives. 
Methods Mol Biol 320:183-191. 
Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L and Ingelman-
Sundberg M (2006) A common novel CYP2C19 gene variant causes ultrarapid drug 
metabolism relevant for the drug response to proton pump inhibitors and 
antidepressants. Clin Pharmacol Ther 79:103-113. 
Sugimoto K, Uno T, Yamazaki H and Tateishi T (2008) Limited frequency of the 
CYP2C19*17 allele and its minor role in a Japanese population. Br J Clin 
Pharmacol 65:437-439. 
Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, 
Miners JO, Birkett DJ and Goldstein JA (1996) The role of the CYP2C9-Leu359 
allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6:341-349. 
                                                                                                         CYP2C19 and CYP2C9: 
                    New aspects of pharmacogenetics and transcriptional regulation 
 
 63
Sumi K, Tanaka T, Uchida A, Magoori K, Urashima Y, Ohashi R, Ohguchi H, Okamura M, 
Kudo H, Daigo K, Maejima T, Kojima N, Sakakibara I, Jiang S, Hasegawa G, Kim 
I, Osborne TF, Naito M, Gonzalez FJ, Hamakubo T, Kodama T and Sakai J (2007) 
Cooperative interaction between hepatocyte nuclear factor 4 alpha and GATA 
transcription factors regulates ATP-binding cassette sterol transporters ABCG5 and 
ABCG8. Mol Cell Biol 27:4248-4260. 
Svensson EC, Tufts RL, Polk CE and Leiden JM (1999) Molecular cloning of FOG-2: a 
modulator of transcription factor GATA-4 in cardiomyocytes. Proc Natl Acad Sci U 
S A 96:956-961. 
Swedenborg E, Power KA, Cai W, Pongratz I and Ruegg J (2009) Regulation of estrogen 
receptor beta activity and implications in health and disease. Cell Mol Life Sci 
66:3873-3894. 
Tamminga WJ, Wemer J, Oosterhuis B, Weiling J, Wilffert B, de Leij LF, de Zeeuw RA and 
Jonkman JH (1999) CYP2D6 and CYP2C19 activity in a large population of Dutch 
healthy volunteers: indications for oral contraceptive-related gender differences. Eur 
J Clin Pharmacol 55:177-184. 
Temsah R and Nemer M (2005) GATA factors and transcriptional regulation of cardiac 
natriuretic peptide genes. Regul Pept 128:177-185. 
Tevosian SG, Deconinck AE, Cantor AB, Rieff HI, Fujiwara Y, Corfas G and Orkin SH 
(1999) FOG-2: A novel GATA-family cofactor related to multitype zinc-finger 
proteins Friend of GATA-1 and U-shaped. Proc Natl Acad Sci U S A 96:950-955. 
Theuretzbacher U, Ihle F and Derendorf H (2006) Pharmacokinetic/pharmacodynamic profile 
of voriconazole. Clin Pharmacokinet 45:649-663. 
Trainor CD, Ghirlando R and Simpson MA (2000) GATA zinc finger interactions modulate 
DNA binding and transactivation. J Biol Chem 275:28157-28166. 
Tsang AP, Visvader JE, Turner CA, Fujiwara Y, Yu C, Weiss MJ, Crossley M and Orkin SH 
(1997) FOG, a multitype zinc finger protein, acts as a cofactor for transcription 
factor GATA-1 in erythroid and megakaryocytic differentiation. Cell 90:109-119. 
Tsuchiya Y, Nakajima M, Kyo S, Kanaya T, Inoue M and Yokoi T (2004) Human CYP1B1 
is regulated by estradiol via estrogen receptor. Cancer Res 64:3119-3125. 
Urquhart BL, Tirona RG and Kim RB (2007) Nuclear receptors and the regulation of drug-
metabolizing enzymes and drug transporters: implications for interindividual 
variability in response to drugs. J Clin Pharmacol 47:566-578. 
van de Stolpe A, Slycke AJ, Reinders MO, Zomer AW, Goodenough S, Behl C, Seasholtz AF 
and van der Saag PT (2004) Estrogen receptor (ER)-mediated transcriptional 
regulation of the human corticotropin-releasing hormone-binding protein promoter: 
differential effects of ERalpha and ERbeta. Mol Endocrinol 18:2908-2923. 
Viger RS, Guittot SM, Anttonen M, Wilson DB and Heikinheimo M (2008) Role of the 
GATA family of transcription factors in endocrine development, function, and 
disease. Mol Endocrinol 22:781-798. 
Visvader JE, Crossley M, Hill J, Orkin SH and Adams JM (1995) The C-terminal zinc finger 
of GATA-1 or GATA-2 is sufficient to induce megakaryocytic differentiation of an 
early myeloid cell line. Mol Cell Biol 15:634-641. 
Walle T, Fagan TC, Walle UK and Topmiller MJ (1996) Stimulatory as well as inhibitory 
effects of ethinyloestradiol on the metabolic clearances of propranolol in young 
women. Br J Clin Pharmacol 41:305-309. 
 
 References  
 
 64
Wang G, Lei HP, Li Z, Tan ZR, Guo D, Fan L, Chen Y, Hu DL, Wang D and Zhou HH 
(2009) The CYP2C19 ultra-rapid metabolizer genotype influences the 
pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol 
65:281-285. 
Welboren WJ, Sweep FC, Span PN and Stunnenberg HG (2009) Genomic actions of estrogen 
receptor alpha: what are the targets and how are they regulated? Endocr Relat 
Cancer 16:1073-1089. 
Whyatt DJ, deBoer E and Grosveld F (1993) The two zinc finger-like domains of GATA-1 
have different DNA binding specificities. EMBO J 12:4993-5005. 
Wortham M, Czerwinski M, He L, Parkinson A and Wan YJ (2007) Expression of 
constitutive androstane receptor, hepatic nuclear factor 4 alpha, and P450 
oxidoreductase genes determines interindividual variability in basal expression and 
activity of a broad scope of xenobiotic metabolism genes in the human liver. Drug 
Metab Dispos 35:1700-1710. 
Xie HG, Kim RB, Stein CM, Wilkinson GR and Wood AJ (1999) Genetic polymorphism of 
(S)-mephenytoin 4'-hydroxylation in populations of African descent. Br J Clin 
Pharmacol 48:402-408. 
Yang JC and Lin CJ (2010) CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics 
of proton pump inhibitor-based therapy of Helicobacter pylori infection. Expert Opin 
Drug Metab Toxicol 6:29-41. 
Yu BN, Chen GL, He N, Ouyang DS, Chen XP, Liu ZQ and Zhou HH (2003) 
Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. 
Drug Metab Dispos 31:1255-1259. 
Zhou SF, Liu JP and Chowbay B (2009) Polymorphism of human cytochrome P450 enzymes 
and its clinical impact. Drug Metab Rev 41:89-295. 
Zhu QS, Qian B and Levy D (2004) Regulation of human microsomal epoxide hydrolase 
gene (EPHX1) expression by the transcription factor GATA-4. Biochim Biophys 
Acta 1676:251-260. 
Zingone MM, Guirguis AB, Airee A and Cobb D (2009) Probable drug interaction between 
warfarin and hormonal contraceptives. Ann Pharmacother 43:2096-2102. 
 
 
 
 
 
